ClinVar Genomic variation as it relates to human health
NM_000518.5(HBB):c.20A>T (p.Glu7Val)
The aggregate germline classification for this variant, typically for a monogenic or Mendelian disorder as in the ACMG/AMP guidelines, or for response to a drug. This value is calculated by NCBI based on data from submitters. Read our rules for calculating the aggregate classification.
Stars represent the aggregate review status, or the level of review supporting the aggregate germline classification for this VCV record. This value is calculated by NCBI based on data from submitters. Read our rules for calculating the review status. The number of submissions which contribute to this review status is shown in parentheses.
No data submitted for somatic clinical impact
No data submitted for oncogenicity
Variant Details
- Identifiers
-
NM_000518.5(HBB):c.20A>T (p.Glu7Val)
Variation ID: 15333 Accession: VCV000015333.154
- Type and length
-
single nucleotide variant, 1 bp
- Location
-
Cytogenetic: 11p15.4 11: 5227002 (GRCh38) [ NCBI UCSC ] 11: 5248232 (GRCh37) [ NCBI UCSC ]
- Timeline in ClinVar
-
First in ClinVar Help The date this variant first appeared in ClinVar with each type of classification.
Last submission Help The date of the most recent submission for each type of classification for this variant.
Last evaluated Help The most recent date that a submitter evaluated this variant for each type of classification.
Germline Oct 5, 2015 Oct 20, 2024 Aug 1, 2024 - HGVS
-
Nucleotide Protein Molecular
consequenceNM_000518.5:c.20A>T MANE Select Help Transcripts from the Matched Annotation from the NCBI and EMBL-EBI (MANE) collaboration.
NP_000509.1:p.Glu7Val missense NC_000011.10:g.5227002T>A NC_000011.9:g.5248232T>A NG_000007.3:g.70614A>T NG_042296.1:g.533T>A NG_046672.1:g.4937T>A NG_059281.1:g.5070A>T LRG_1232:g.5070A>T LRG_1232t1:c.20A>T LRG_1232p1:p.Glu7Val P68871:p.Glu7Val - Protein change
- E7V
- Other names
-
E6V
HbS
- Canonical SPDI
- NC_000011.10:5227001:T:A
-
Functional
consequence HelpThe effect of the variant on RNA or protein function, based on experimental evidence from submitters.
- -
-
Global minor allele
frequency (GMAF) HelpThe global minor allele frequency calculated by the 1000 Genomes Project. The minor allele at this location is indicated in parentheses and may be different from the allele represented by this VCV record.
-
0.02736 (A)
-
Allele frequency
Help
The frequency of the allele represented by this VCV record.
-
The Genome Aggregation Database (gnomAD), exomes 0.00348
Exome Aggregation Consortium (ExAC) 0.00438
The Genome Aggregation Database (gnomAD) 0.01298
1000 Genomes Project 0.02736
1000 Genomes Project 30x 0.02873
- Links
-
UniProtKB: P68871#VAR_002863 OMIM: 141900.0039 OMIM: 141900.0040 OMIM: 141900.0243 OMIM: 141900.0244 OMIM: 141900.0245 OMIM: 141900.0246 OMIM: 141900.0247 OMIM: 141900.0521 OMIM: 141900.0523 dbSNP: rs334 ClinGen: CA125138 Genetic Testing Registry (GTR): GTR000500319 Genetic Testing Registry (GTR): GTR000556525 Genetic Testing Registry (GTR): GTR000556557 VarSome
Genes
Gene | OMIM | ClinGen Gene Dosage Sensitivity Curation |
Variation Viewer
Help
Links to Variation Viewer, a genome browser to view variation data from NCBI databases. |
Related variants | ||
---|---|---|---|---|---|---|
HI score
Help
The haploinsufficiency score for the gene, curated by ClinGen’s Dosage Sensitivity Curation task team. |
TS score
Help
The triplosensitivity score for the gene, curated by ClinGen’s Dosage Sensitivity Curation task team. |
Within gene
Help
The number of variants in ClinVar that are contained within this gene, with a link to view the list of variants. |
All
Help
The number of variants in ClinVar for this gene, including smaller variants within the gene and larger CNVs that overlap or fully contain the gene. |
|||
HBB | - | - |
GRCh38 GRCh37 |
22 | 1834 | |
LOC106099062 | - | - | - | GRCh38 | - | 862 |
LOC107133510 | - | - | - | GRCh38 | - | 1784 |
Conditions - Germline
Condition
Help
The condition for this variant-condition (RCV) record in ClinVar. |
Classification
Help
The aggregate germline classification for this variant-condition (RCV) record in ClinVar. The number of submissions that contribute to this aggregate classification is shown in parentheses. (# of submissions) |
Review status
Help
The aggregate review status for this variant-condition (RCV) record in ClinVar. This value is calculated by NCBI based on data from submitters. Read our rules for calculating the review status. |
Last evaluated
Help
The most recent date that a submitter evaluated this variant for the condition. |
Variation/condition record
Help
The RCV accession number, with most recent version number, for the variant-condition record, with a link to the RCV web page. |
---|---|---|---|---|
not provided (1) |
no classification provided
|
Sep 15, 2023 | RCV000016573.22 | |
Pathogenic (22) |
criteria provided, multiple submitters, no conflicts
|
Apr 22, 2024 | RCV000016574.81 | |
protective (1) |
no assertion criteria provided
|
Dec 2, 2011 | RCV000016575.45 | |
Pathogenic (17) |
criteria provided, multiple submitters, no conflicts
|
Aug 1, 2024 | RCV000224000.62 | |
Pathogenic (1) |
no assertion criteria provided
|
Feb 23, 2016 | RCV000477892.10 | |
Pathogenic (6) |
criteria provided, multiple submitters, no conflicts
|
Oct 18, 2019 | RCV000576548.24 | |
Pathogenic (1) |
criteria provided, single submitter
|
Oct 13, 2023 | RCV000623118.11 | |
Pathogenic (1) |
no assertion criteria provided
|
Jul 19, 2018 | RCV000723337.12 | |
Pathogenic (1) |
criteria provided, single submitter
|
Oct 14, 2019 | RCV001192494.9 | |
Pathogenic (1) |
no assertion criteria provided
|
Jan 16, 2020 | RCV001255121.9 | |
Pathogenic (1) |
criteria provided, single submitter
|
Jun 30, 2021 | RCV001535873.11 | |
Pathogenic (4) |
criteria provided, multiple submitters, no conflicts
|
Mar 5, 2022 | RCV001824571.15 | |
See cases
|
Pathogenic (1) |
criteria provided, single submitter
|
Jan 6, 2022 | RCV002251908.9 |
Pathogenic (4) |
criteria provided, multiple submitters, no conflicts
|
Jul 22, 2022 | RCV002288496.12 | |
Pathogenic (1) |
criteria provided, single submitter
|
Feb 17, 2023 | RCV003150808.8 | |
Pathogenic (1) |
criteria provided, single submitter
|
Mar 25, 2024 | RCV003989286.2 | |
click to load more click to collapse |
Submissions - Germline
Classification
Help
The submitted germline classification for each SCV record. (Last evaluated) |
Review status
Help
Stars represent the review status, or the level of review supporting the submitted (SCV) record. This value is calculated by NCBI based on data from the submitter. Read our rules for calculating the review status. This column also includes a link to the submitter’s assertion criteria if provided, and the collection method. (Assertion criteria) |
Condition
Help
The condition for the classification, provided by the submitter for this submitted (SCV) record. This column also includes the affected status and allele origin of individuals observed with this variant. |
Submitter
Help
The submitting organization for this submitted (SCV) record. This column also includes the SCV accession and version number, the date this SCV first appeared in ClinVar, and the date that this SCV was last updated in ClinVar. |
More information
Help
This column includes more information supporting the classification, including citations, the comment on classification, and detailed evidence provided as observations of the variant by the submitter. |
|
---|---|---|---|---|---|
Pathogenic
(Apr 16, 2018)
|
criteria provided, single submitter
Method: research
|
Hb SS disease
Affected status: unknown, yes
Allele origin:
unknown,
paternal,
maternal
|
HudsonAlpha Institute for Biotechnology, HudsonAlpha Institute for Biotechnology
Study: CSER-HudsonAlpha
Accession: SCV000584093.2 First in ClinVar: Jul 29, 2017 Last updated: Jun 30, 2018 |
Observation 1:
Number of individuals with the variant: 1
Observation 2:
Number of individuals with the variant: 1
Observation 3:
Number of individuals with the variant: 1
Observation 4:
Number of individuals with the variant: 1
Observation 5:
Number of individuals with the variant: 1
Observation 6:
Number of individuals with the variant: 1
Observation 7:
Number of individuals with the variant: 1
Observation 8:
Number of individuals with the variant: 1
Observation 9:
Number of individuals with the variant: 1
|
|
Pathogenic
(Dec 19, 2014)
|
criteria provided, single submitter
Method: clinical testing
|
not provided
Affected status: unknown
Allele origin:
germline
|
Eurofins Ntd Llc (ga)
Accession: SCV000224235.3
First in ClinVar: Jun 28, 2015 Last updated: Dec 19, 2017 |
Number of individuals with the variant: 5
Sex: mixed
|
|
Pathogenic
(Oct 14, 2019)
|
criteria provided, single submitter
Method: clinical testing
|
Sickle cell disease and related diseases
Affected status: unknown
Allele origin:
germline
|
Women's Health and Genetics/Laboratory Corporation of America, LabCorp
Accession: SCV001360653.1
First in ClinVar: Jun 22, 2020 Last updated: Jun 22, 2020 |
Comment:
Variant summary: HBB c.20A>T (p.Glu7Val) results in a non-conservative amino acid change located in the Globin domain (IPR000971) of the encoded protein sequence. Four of … (more)
Variant summary: HBB c.20A>T (p.Glu7Val) results in a non-conservative amino acid change located in the Globin domain (IPR000971) of the encoded protein sequence. Four of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 0.0035 in 251180 control chromosomes in the gnomAD database, including 3 homozygotes. c.20A>T has been reported in the literature in multiple individuals affected with Sickle Cell Disease, an inherited monogenic disease characterized by intravascular sickling, haemolysis, anemia and leukocytosis as well as the association between sickled red blood cells and other blood components (example, Domingos_2014). These data indicate that the variant is very likely to be associated with disease. At least one publication reports experimental evidence evaluating an impact on protein function. The most pronounced variant effect results in decreased solubility of deoxygenated Hb S, and polymerization which leads to the formation of an extensive network of fibers in red blood cells (example, Adachi_1991). Eleven clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. (less)
|
|
Pathogenic
(May 09, 2018)
|
criteria provided, single submitter
Method: clinical testing
|
Hb SS disease
Affected status: yes
Allele origin:
germline
|
Institute for Genomic Medicine (IGM) Clinical Laboratory, Nationwide Children's Hospital
Accession: SCV001423600.1
First in ClinVar: Jul 27, 2020 Last updated: Jul 27, 2020 |
Comment:
[ACMG/AMP: PS3, PM3, PM5, PS4_Moderate, PP5] This alteration is supported by well-established in vitro or in vivo functional studies to have a damaging effect on … (more)
[ACMG/AMP: PS3, PM3, PM5, PS4_Moderate, PP5] This alteration is supported by well-established in vitro or in vivo functional studies to have a damaging effect on protein function or splicing [PS3], is detected in trans with a known pathogenic variant [PM3], is a novel missense change at an amino residue where a different missense change has been deemed to be pathogenic [PM5], has previously been observed in multiple unrelated patients with the same phenotype [PS4_Moderate], was reported as a pathogenic/likely pathogenic alteration by a reputable source (ClinVar or other correspondence from a clinical testing laboratory) [PP5]. (less)
|
|
Pathogenic
(Mar 02, 2016)
|
criteria provided, single submitter
Method: clinical testing
|
not provided
Affected status: yes
Allele origin:
germline
|
Clinical Genetics and Genomics, Karolinska University Hospital
Accession: SCV001450316.1
First in ClinVar: Dec 12, 2020 Last updated: Dec 12, 2020 |
Number of individuals with the variant: 32
|
|
Pathogenic
(Jun 30, 2021)
|
criteria provided, single submitter
Method: clinical testing
|
Heinz body anemia
Hereditary persistence of fetal hemoglobin Dominant beta-thalassemia Hb SS disease alpha Thalassemia Malaria, susceptibility to Beta-thalassemia HBB/LCRB METHEMOGLOBINEMIA, BETA TYPE Erythrocytosis, familial, 6
Affected status: unknown
Allele origin:
unknown
|
Fulgent Genetics, Fulgent Genetics
Accession: SCV001752492.1
First in ClinVar: Jul 18, 2021 Last updated: Jul 18, 2021
Comment:
This variant has been detected in individual(s) who were sent for testing of Renasight - kidney gene panel.
|
|
|
Pathogenic
(Sep 22, 2021)
|
criteria provided, single submitter
Method: clinical testing
|
Hb SS disease
Affected status: yes
Allele origin:
germline
|
Centogene AG - the Rare Disease Company
Accession: SCV002028318.1
First in ClinVar: Dec 04, 2021 Last updated: Dec 04, 2021 |
|
|
Pathogenic
(Jan 11, 2022)
|
criteria provided, single submitter
Method: clinical testing
|
Hb SS disease
Affected status: yes
Allele origin:
unknown
|
Baylor Genetics
Study: CSER-TexasKidsCanSeq
Accession: SCV002030204.2 First in ClinVar: Dec 12, 2021 Last updated: Feb 13, 2022 |
Comment:
This variant was determined to be pathogenic according to ACMG Guidelines, 2015 [PMID:25741868].
|
|
Pathogenic
(Jan 06, 2022)
|
criteria provided, single submitter
Method: clinical testing
|
See cases
Affected status: yes
Allele origin:
germline
|
Laboratorio de Genetica e Diagnostico Molecular, Hospital Israelita Albert Einstein
Accession: SCV002522968.1
First in ClinVar: Jun 11, 2022 Last updated: Jun 11, 2022 |
Comment:
ACMG classification criteria: PS3, PS4, PM3, BS1
Clinical Features:
Upper limb phocomelia (present) , Congenital hypothyroidism (present) , Cleft palate (present) , Abnormal heart morphology (present)
|
|
Pathogenic
(Jul 22, 2022)
|
criteria provided, single submitter
Method: clinical testing
|
Beta-thalassemia HBB/LCRB
Affected status: yes
Allele origin:
germline
|
MGZ Medical Genetics Center
Accession: SCV002581124.1
First in ClinVar: Oct 15, 2022 Last updated: Oct 15, 2022
Comment:
ACMG criteria applied: PM3_VSTR, PP1_VSTR, PS4, PM1, PM5, PP4
|
Number of individuals with the variant: 5
Sex: male
|
|
Pathogenic
(Oct 12, 2022)
|
criteria provided, single submitter
Method: research
|
Hb SS disease
(Autosomal recessive inheritance)
Affected status: unknown
Allele origin:
germline
|
H3Africa Consortium
Study: H3Africa
Accession: SCV002014636.2 First in ClinVar: Nov 13, 2021 Last updated: Oct 15, 2022 |
Comment:
While the frequency of the alternate allele in gnoMAD v2.0.2 is 0.53, its frequency in African populations is >5%, as there is a high prevalence … (more)
While the frequency of the alternate allele in gnoMAD v2.0.2 is 0.53, its frequency in African populations is >5%, as there is a high prevalence of sickle cell disease in African ancestry individuals. (less)
|
|
Pathogenic
(Aug 10, 2022)
|
criteria provided, single submitter
Method: clinical testing
|
Hb SS disease
Affected status: yes
Allele origin:
germline
|
Greenwood Genetic Center Diagnostic Laboratories, Greenwood Genetic Center
Accession: SCV002583820.1
First in ClinVar: Oct 22, 2022 Last updated: Oct 22, 2022 |
Comment:
PS3, PS4, PM3, PP1
|
|
Pathogenic
(Sep 06, 2019)
|
criteria provided, single submitter
Method: clinical testing
|
Beta-thalassemia HBB/LCRB
Affected status: yes
Allele origin:
germline
|
Genetics and Molecular Pathology, SA Pathology
Additional submitter:
Shariant Australia, Australian Genomics
Accession: SCV002556466.2
First in ClinVar: Aug 08, 2022 Last updated: Dec 17, 2022 |
|
|
Pathogenic
(Aug 28, 2019)
|
criteria provided, single submitter
Method: clinical testing
|
beta Thalassemia
(Autosomal recessive inheritance)
Affected status: no
Allele origin:
germline
|
Victorian Clinical Genetics Services, Murdoch Childrens Research Institute
Additional submitter:
Shariant Australia, Australian Genomics
Accession: SCV002767565.1
First in ClinVar: Dec 24, 2022 Last updated: Dec 24, 2022 |
Comment:
A heterozygous missense variant, NM_000518.5(HBB):c.20A>T, has been identified in exon 1 of 3 of the HBB gene. The variant is predicted to result in a … (more)
A heterozygous missense variant, NM_000518.5(HBB):c.20A>T, has been identified in exon 1 of 3 of the HBB gene. The variant is predicted to result in a major amino acid change from glutamic acid to valine at position 7 of the protein (NP_000509.1(HBB):p.(Glu7Val)). The glutamic acid at this position has low conservation (100 vertebrates, UCSC), and is located within the Hb-beta like functional domain. In silico predictions of pathogenicity for this variant are conflicting (Polyphen, SIFT, CADD, Mutation Taster). The variant is present in the gnomAD database at a frequency of 0.4% (1228 heterozygous, 4 homozygous). An alternative residue change has been reported in the gnomAD database at a frequency of 0.1%. The variant is the cause of hemoglobin S which results in sickle cell anemia and has been previously described as pathogenic and segregated with disease in multiple families (ClinVar; Kwiatkowski, D.P. 2005). Even though often fatal when homozygous or compound heterozygous, it is seen in high frequency (~10%) in populations in Sub-Saharan African and Middle East where it has been positively selected because it confers protection against malaria in heterozygous individuals, which are asymptomatic (Kwiatkowski, D.P. 2005). Additionally, functional studies showed that erythrocytes from transgenic mice expressing human HBB sickle readily on deoxygenation (Greaves, D.R. et al., 1990). A different variant in the same codon resulting in a change to lysine has been reported to cause a mild hemolytic anemia (ClinVar; Kwiatkowski, D.P. 2005). Based on the information available at the time of curation, this variant has been classified as PATHOGENIC. (less)
|
|
Pathogenic
(May 25, 2021)
|
criteria provided, single submitter
Method: clinical testing
|
Not Provided
Affected status: yes
Allele origin:
germline
|
GeneDx
Accession: SCV000321760.8
First in ClinVar: Oct 09, 2016 Last updated: Mar 04, 2023 |
Comment:
Functional studies using transgenic mouse models showed mouse erythrocytes with this variant sickled upon deoxygenation (Greaves et al., 1990) and kinetic studies indicate this variant … (more)
Functional studies using transgenic mouse models showed mouse erythrocytes with this variant sickled upon deoxygenation (Greaves et al., 1990) and kinetic studies indicate this variant drastically decreases the molecular stability of the protein (Adachi et al., 1987); Commonly referred to as p.(E6V) due to the use of alternate nomenclature; This variant is associated with the following publications: (PMID: 20825310, 1802884, 30315176, 3267215, 24123366, 20954261, 22975760, 23065522, 22625666, 19465909, 20305663, 20981092, 22010933, 22028795, 22957039, 23144702, 2296310, 27884173, 27254408, 17393956, 28356267, 26372199, 19758965, 12124399, 22244832, 20861612, 30655275, 30290004, 21329186, 15543018, 30033078, 31553106, 31130284, 31980526, 27650483, 32817264, 32371413, 25023084, 2888754, 31589614, 25087612) (less)
|
|
Pathogenic
(Apr 29, 2021)
|
criteria provided, single submitter
Method: clinical testing
|
Hb SS disease
Affected status: unknown
Allele origin:
unknown
|
Baylor Genetics
Accession: SCV001163295.2
First in ClinVar: Mar 01, 2020 Last updated: Mar 11, 2023 |
|
|
Pathogenic
(Feb 17, 2023)
|
criteria provided, single submitter
Method: clinical testing
|
Sickle cell-hemoglobin C disease
Affected status: unknown
Allele origin:
germline
|
Johns Hopkins Genomics, Johns Hopkins University
Accession: SCV003839051.1
First in ClinVar: Mar 11, 2023 Last updated: Mar 11, 2023 |
Comment:
This HBB variant (rs334) reaches polymorphic frequency (>1%) within the African/African American subpopulation in a large population dataset (gnomAD: 1121/24964 total alleles; 4.49%; 4 homozygotes) … (more)
This HBB variant (rs334) reaches polymorphic frequency (>1%) within the African/African American subpopulation in a large population dataset (gnomAD: 1121/24964 total alleles; 4.49%; 4 homozygotes) and has been reported in ClinVar. It is the most common pathogenic HBB variant in individuals of African ancestry. Also known as p.Glu6Val and HbS, it has been reported in a homozygous or compound heterozygous state in individuals with beta-hemoglobinopathies. One bioinformatic tool queried predicts that this substitution would damaging, while another predicts it would be tolerated. Experimental studies have shown that this variant affects the physical and kinetic properties of the hemoglobin protein. Bioinformatic analysis predicts that this missense variant would not affect normal exon 1 splicing, although this has not been confirmed experimentally to our knowledge. We consider c.20A>T (p.Glu7Val) to be pathogenic. (less)
|
|
Pathogenic
(May 06, 2023)
|
criteria provided, single submitter
Method: clinical testing
|
Hb SS disease
Affected status: unknown
Allele origin:
unknown
|
Illumina Laboratory Services, Illumina
Accession: SCV000914520.2
First in ClinVar: May 27, 2019 Last updated: Jul 22, 2023 |
Comment:
The HBB c.20A>T (p.Glu7Val) missense variant, also referred to as p.Glu6Val, has been reported in a homozygous state in more than 1000 individuals with sickle … (more)
The HBB c.20A>T (p.Glu7Val) missense variant, also referred to as p.Glu6Val, has been reported in a homozygous state in more than 1000 individuals with sickle cell anemia (PMID: 25023084; 25023085; 26275168). The highest frequency of this allele in the Genome Aggregation Database is 0.04490 in the African/African-American population (version 2.1.1). This frequency is high, however, carriers are hypothesized to confer protection against Plasmodium falciparum malaria infection (PMID: 21045822). In mice expressing the sickle trait variant, erythrocytes were shown to sickle with deoxygenation, similar to that seen in humans with sickle cell anemia (PMID: 2296310), and in mice with 100% expression of the sickle cell variant, chronic hemolytic anemia with circulating sickled erythrocytes, as well as chronic tissue damage, was observed (PMID: 12124399). Based on the available evidence, the c.20A>T (p.Glu7Val) variant is classified as pathogenic for sickle cell disease. (less)
|
|
Pathogenic
(Oct 29, 2023)
|
criteria provided, single submitter
Method: clinical testing
|
not provided
Affected status: unknown
Allele origin:
germline
|
Revvity Omics, Revvity
Accession: SCV002024975.3
First in ClinVar: Nov 29, 2021 Last updated: Feb 04, 2024 |
|
|
Pathogenic
(Jan 31, 2024)
|
criteria provided, single submitter
Method: clinical testing
|
not provided
Affected status: unknown
Allele origin:
germline
|
Labcorp Genetics (formerly Invitae), Labcorp
Accession: SCV000949988.7
First in ClinVar: Aug 14, 2019 Last updated: Feb 20, 2024 |
Comment:
This sequence change replaces glutamic acid, which is acidic and polar, with valine, which is neutral and non-polar, at codon 7 of the HBB protein … (more)
This sequence change replaces glutamic acid, which is acidic and polar, with valine, which is neutral and non-polar, at codon 7 of the HBB protein (p.Glu7Val). This variant is present in population databases (rs334, gnomAD 5%), and has an allele count higher than expected for a pathogenic variant. This missense change has been observed in individuals with sickle cell disease (PMID: 19758965, 20301551, 20861612, 26372199). This variant is also known as p.Glu6Val and HbS. ClinVar contains an entry for this variant (Variation ID: 15333). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on HBB protein function. Experimental studies have shown that this missense change affects HBB function (PMID: 1802884, 12124399, 28356267). For these reasons, this variant has been classified as Pathogenic. (less)
|
|
Pathogenic
(Nov 29, 2023)
|
criteria provided, single submitter
Method: clinical testing
|
not provided
Affected status: unknown
Allele origin:
germline
|
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories
Accession: SCV000603887.10
First in ClinVar: Sep 30, 2017 Last updated: Feb 20, 2024 |
Comment:
The Hb S variant (HBB: c.20A>T; p.Glu7Val, also known as Glu6Val when numbered from the mature protein, HbVar ID: 226, rs334) is a common pathogenic … (more)
The Hb S variant (HBB: c.20A>T; p.Glu7Val, also known as Glu6Val when numbered from the mature protein, HbVar ID: 226, rs334) is a common pathogenic beta globin variant. Heterozygosity for Hb S is consistent with sickle cell trait. Homozygosity for Hb S results in sickle cell anemia. Hb S in combination with a different pathogenic HBB variant on the opposite chromosome results in various forms of sickle cell disease (see HbVar link and references therein). References: Link to HbVar database: https://globin.bx.psu.edu/hbvar/menu.html (less)
|
|
Pathogenic
(Apr 11, 2024)
|
criteria provided, single submitter
Method: clinical testing
|
Hb SS disease
(Autosomal recessive inheritance)
Affected status: unknown
Allele origin:
germline
|
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine
Accession: SCV000967671.2
First in ClinVar: Aug 26, 2019 Last updated: Apr 20, 2024 |
Comment:
The p.Glu7Val variant (also known as p.Glu6Val or hemoglobin S variant) in HBB is a well-established variant which, in the homozygous state, causes sickle cell … (more)
The p.Glu7Val variant (also known as p.Glu6Val or hemoglobin S variant) in HBB is a well-established variant which, in the homozygous state, causes sickle cell anemia and which accounts for 60-70% of sickle cell disease in the US (Bender 2003 PMID: 20301551, Serjeant 1968 PMID: 4232783). Co-inheritance with a second HBB variant associated with abnormal hemoglobin (such as Hb C, Hb D, Hb O, Hb E and β-thalassemia pathogenic variants) also results in sickle cell disease. This variant has also been reported by other clinical laboratories in ClinVar (Variation ID 15333) and has been identified in 1799/41432 (4.3%) of African/African American chromosomes, including 9 homozygotes, by gnomAD (http://gnomad.broadinstitute.org, v.3.1.2). In vitro functional studies support an impact on protein function as this variant is shown to affect hemoglobin polymerization, resulting in abnormally shaped red blood cells (He 2017 PMID: 12124399, Adachi 1991 PMID: 1802884). Transgenic mouse models have also shown that this variant causes sickle cell disease, as mouse red blood cells with the variant had a sickle shape upon deoxygenation (Greaves 1990 PMID: 2296310). In summary, this variant meets criteria to be classified as pathogenic autosomal recessive sickle cell disease. ACMG/AMP Criteria applied: PM3_Very Strong, PS3. (less)
|
|
Pathogenic
(Feb 24, 2023)
|
criteria provided, single submitter
Method: clinical testing
|
Not provided
Affected status: unknown
Allele origin:
germline
|
Mayo Clinic Laboratories, Mayo Clinic
Accession: SCV001714970.3
First in ClinVar: Jun 15, 2021 Last updated: Jun 02, 2024 |
Number of individuals with the variant: 203
|
|
Pathogenic
(-)
|
criteria provided, single submitter
Method: clinical testing
|
Beta-thalassemia HBB/LCRB
(Autosomal recessive inheritance)
Affected status: yes
Allele origin:
germline
|
Neuberg Centre For Genomic Medicine, NCGM
Accession: SCV005060996.1
First in ClinVar: Jun 17, 2024 Last updated: Jun 17, 2024 |
Comment:
The missense c.20A>T (p.Glu7Val) variant in HBB gene has been reported previously in homozygous and compound heterozygous state in multiple individuals affected with HBB-related sickle … (more)
The missense c.20A>T (p.Glu7Val) variant in HBB gene has been reported previously in homozygous and compound heterozygous state in multiple individuals affected with HBB-related sickle cell anemia (Akinbami et al. 2016; Meher et al. 2016). Experimental studies have shown that this mutation (Glu7Val) in hemoglobin (Hb) causes red blood cells to assume a rigid curved shape that blocks their passage through the vasculature resulting in ischemia, severe pain, and necrosis (Eshbach et al. 2017). The p.Glu7Val variant has 0.4% allele frequency in gnomAD exomes database. This variant has been reported to the ClinVar database as Pathogenic (multiple submissions). The amino acid change p.Glu7Val in HBB is predicted as conserved by GERP++ and PhyloP across 100 vertebrates. The amino acid Glutamic acid at position 7 is changed to a Valine changing protein sequence and it might alter its composition and physico-chemical properties. For these reasons, this variant has been classified as Pathogenic. (less)
Clinical Features:
Abnormality of blood and blood-forming tissues (present)
|
|
Pathogenic
(Sep 15, 2014)
|
criteria provided, single submitter
Method: clinical testing
|
not provided
Affected status: not provided
Allele origin:
germline
|
Center for Pediatric Genomic Medicine, Children's Mercy Hospital and Clinics
Accession: SCV000281507.1
First in ClinVar: Jun 08, 2016 Last updated: Jun 08, 2016 |
|
|
Pathogenic
(Jun 29, 2018)
|
criteria provided, single submitter
Method: clinical testing
|
SICKLE CELL ANEMIA
Affected status: yes
Allele origin:
germline
|
Rady Children's Institute for Genomic Medicine, Rady Children's Hospital San Diego
Accession: SCV000996163.1
First in ClinVar: Oct 20, 2019 Last updated: Oct 20, 2019 |
Comment:
The c.20A>T (p.Glu7Val) variant in HBB (also known as p.Glu6Val) is the most prevalent genotype associated with sickle cell disease (PMID: 25203083). This variant is … (more)
The c.20A>T (p.Glu7Val) variant in HBB (also known as p.Glu6Val) is the most prevalent genotype associated with sickle cell disease (PMID: 25203083). This variant is an established disease-associated mutation and has been reported as pathogenic by multiple clinical diagnostic laboratories in ClinVar (variant ID: 15333). Based on the available evidence, the c.20A>T (p.Glu7Val) variant is classified as pathogenic. (less)
Number of individuals with the variant: 1
|
|
Pathogenic
(May 28, 2019)
|
criteria provided, single submitter
Method: clinical testing
|
Beta-thalassemia HBB/LCRB
Affected status: unknown
Allele origin:
unknown
|
Mendelics
Accession: SCV001138222.1
First in ClinVar: Jan 13, 2020 Last updated: Jan 13, 2020 |
|
|
Pathogenic
(Oct 18, 2019)
|
criteria provided, single submitter
Method: clinical testing
|
Beta-thalassemia HBB/LCRB
Affected status: unknown
Allele origin:
unknown
|
Myriad Genetics, Inc.
Accession: SCV001194011.2
First in ClinVar: Apr 06, 2020 Last updated: Jul 06, 2020 |
Comment:
NM_000518.4(HBB):c.20A>T(E7V, aka Hb S) is classified as pathogenic and is associated with hemoglobin S (sickle cell disease). Sources cited for classification include the following: PMID … (more)
NM_000518.4(HBB):c.20A>T(E7V, aka Hb S) is classified as pathogenic and is associated with hemoglobin S (sickle cell disease). Sources cited for classification include the following: PMID 19061217, 2582106, 22028795, 22625666, 22010933, 2888754, 20954261, 6583683, 1376298. Classification of NM_000518.4(HBB):c.20A>T(E7V, aka Hb S) is based on the following criteria: This is a well-established pathogenic variant in the literature that has been observed more frequently in patients with clinical diagnoses than in healthy populations. Please note: this variant was assessed in the context of healthy population screening.‚Äã (less)
|
|
Pathogenic
(Mar 10, 2021)
|
criteria provided, single submitter
Method: clinical testing
|
Hb SS disease
Affected status: yes
Allele origin:
germline
|
Al Jalila Children’s Genomics Center, Al Jalila Childrens Speciality Hospital
Accession: SCV001984022.1
First in ClinVar: Oct 30, 2021 Last updated: Oct 30, 2021
Comment:
The p.Glu7Val variant (also known as Glu6Val and hemoglobin S variant) in HBB has been identified in 1121/24964 (4.5% 4 homozygotes) of African chromosomes by … (more)
The p.Glu7Val variant (also known as Glu6Val and hemoglobin S variant) in HBB has been identified in 1121/24964 (4.5% 4 homozygotes) of African chromosomes by the Genome Aggregation Database. In the homozygous state the p.Glu7Val variant in HBB causes sickle cell anemia. Co-inheritance with a second HBB variant associated with abnormal hemoglobin (such as Hb C Hb D Hb O Hb E and β-thalassemia pathogenic variants) results in sickle cell disease (PMID: 20301551). In summary this variant meets our criteria to be classified as pathogenic for sickle cell disease. (less)
|
|
|
Pathogenic
(Jan 03, 2022)
|
criteria provided, single submitter
Method: clinical testing
|
Hb SS disease
Affected status: yes
Allele origin:
germline
|
3billion
Accession: SCV002058326.1
First in ClinVar: Jan 08, 2022 Last updated: Jan 08, 2022 |
Comment:
Same nucleotide change resulting in same amino acid change has been previously reported as pathogenic/likely pathogenic with strong evidence (ClinVar ID: VCV000015333, PMID:3267215, PS1_S). The … (more)
Same nucleotide change resulting in same amino acid change has been previously reported as pathogenic/likely pathogenic with strong evidence (ClinVar ID: VCV000015333, PMID:3267215, PS1_S). The variant has been observed in multiple (>3) similarly affected unrelated individuals(PMID: 25023084, 25203083, 25023085, PS4_S). Functional studies provide strong evidence of the variant having a damaging effect on the gene or gene product (PMID: 1802884, 2296310, 28356267, 12124399, PS3_S). The variant has been reported to be in trans with a pathogenic variant as either compound heterozygous or homozygous in at least one similarly affected unrelated individual (PMID: 23591685, 29542687, PM3_M). A different missense change at the same codon has been reported as pathogenic/likely pathogenic with strong evidence (ClinVar ID: VCV000015126,VCV000036301, PMID:19460936,6129204,8294201, PM5_M). In silico tool predictions suggest damaging effect of the variant on gene or gene product (3CNET: 0.83, PP3_P). Therefore, this variant is classified as pathogenic according to the recommendation of ACMG/AMP guideline. (less)
Clinical Features:
Hemolytic anemia (present) , Anemia (present)
|
|
Pathogenic
(Dec 28, 2021)
|
criteria provided, single submitter
Method: clinical testing
|
Hb SS disease
(Autosomal recessive inheritance)
Affected status: yes
Allele origin:
biparental
|
Genomics Facility, Ludwig-Maximilians-Universität München
Accession: SCV002073896.1
First in ClinVar: Feb 13, 2022 Last updated: Feb 13, 2022 |
Clinical Features:
Increased red cell sickling tendency (present) , Hemolytic anemia (present) , Sickled erythrocytes (present)
Age: 0-9 years
Sex: female
Tissue: PBMCs
Method: Agilent V6+UTR exome enrichment, Illumina NextSeq 500 sequencing
|
|
Pathogenic
(Feb 10, 2021)
|
criteria provided, single submitter
Method: clinical testing
|
Hb SS disease
Affected status: yes
Allele origin:
germline
|
New York Genome Center
Study: CSER-NYCKidSeq
Accession: SCV002097812.1 First in ClinVar: Feb 20, 2022 Last updated: Feb 20, 2022 |
Comment:
The c.20A>T (p.Glu7Val) variant in HBB (also known as p.Glu6Val) is the most prevalent genotype associated with sickle cell disease [PMID: 25203083]. This variant is … (more)
The c.20A>T (p.Glu7Val) variant in HBB (also known as p.Glu6Val) is the most prevalent genotype associated with sickle cell disease [PMID: 25203083]. This variant is an established disease-associated mutation and has been reported as pathogenic by multiple clinical diagnostic laboratories in ClinVar (variant ID: 15333). This variant is identified in gnomAD in 1826 heterozygous individuals, 9 homozygous individuals, with an allele frequency of 1.27e-2. Based on the available evidence, the c.20A>T (p.Glu7Val) variant is classified as pathogenic. (less)
Clinical Features:
Seizure (present) , Delayed speech and language development (present) , Hematuria (present)
Secondary finding: no
|
|
Pathogenic
(Mar 05, 2022)
|
criteria provided, single submitter
Method: clinical testing
|
HBB-related disorder
Affected status: yes
Allele origin:
germline
|
DASA
Accession: SCV002107097.2
First in ClinVar: Mar 28, 2022 Last updated: Apr 02, 2022 |
Comment:
Well-established in vitro or in vivo functional studies supportive of a damaging effect on the gene or gene product (PMID: 13464827; 11880644; 11830454; 12124399; 28356267; … (more)
Well-established in vitro or in vivo functional studies supportive of a damaging effect on the gene or gene product (PMID: 13464827; 11880644; 11830454; 12124399; 28356267; 1802884) - PS3.The c.20A>T;p.(Glu7Val) missense variant has been observed in affected individual(s) and ClinVar contains an entry for this variant (ClinVar ID: 15333; PMID: 20301551; PMID: 30002798; PMID: 15658184;PMID: 7384810; PMID: 6268660; PMID: 26372199; PMID: 26275168; PMID: 28356267; PMID: 22625666; PMID: 32527859) - PS4. The p.(Glu7Val) was detected in trans with a pathogenic variant (PMID: 15658184; PMID: 20861612; PMID: 21131035) - PM3_very strong. Pathogenic missense variant in this residue have been reported (ClinVar ID: 15126 PMID: 20301551; 27117572; 26372199) - PM5. The variant co-segregated with disease in multiple affected family members (PMID: 21302591; 34334128; 14084634; 26041415) - PP1_strong.and allele frequency is greater than expected for disorder - BS1. In summary, the currently available evidence indicates that the variant is pathogenic. (less)
Number of individuals with the variant: 2
Sex: female
Geographic origin: Brazil
|
|
Pathogenic
(Nov 22, 2021)
|
criteria provided, single submitter
Method: clinical testing
|
Not provided
Affected status: yes
Allele origin:
germline
|
AiLife Diagnostics, AiLife Diagnostics
Accession: SCV002502707.1
First in ClinVar: Apr 23, 2022 Last updated: Apr 23, 2022 |
Number of individuals with the variant: 3
Secondary finding: yes
|
|
Pathogenic
(Feb 06, 2020)
|
criteria provided, single submitter
Method: clinical testing
|
Hb SS disease
(Autosomal recessive inheritance)
Affected status: yes
Allele origin:
germline
|
Genetics and Molecular Pathology, SA Pathology
Additional submitter:
Shariant Australia, Australian Genomics
Accession: SCV002556497.2
First in ClinVar: Aug 08, 2022 Last updated: Dec 17, 2022 |
Comment:
PS4, PS3, PP1, PP5, PP4.
|
|
Pathogenic
(-)
|
criteria provided, single submitter
Method: clinical testing
|
Hb SS disease
(Autosomal recessive inheritance)
Affected status: yes
Allele origin:
germline
|
Lifecell International Pvt. Ltd
Accession: SCV003845197.1
First in ClinVar: Apr 01, 2023 Last updated: Apr 01, 2023 |
Comment:
A Heterozygous Missense variant c.20A>T in Exon 1 of the HBB gene that results in the amino acid substitution p.Glu7Val was identified. The observed variant … (more)
A Heterozygous Missense variant c.20A>T in Exon 1 of the HBB gene that results in the amino acid substitution p.Glu7Val was identified. The observed variant has a minor allele frequency of 0.00348% in gnomAD exomes and genomes, respectively. The severity of the impact of this variant on the protein is medium, based on the effect of the protein and REVEL score. Rare Exome Variant Ensemble Learner (REVEL) is an ensembl method for predicting the pathogenicity of missense variants based on a combination of scores from 13 individual tools: MutPred, FATHMM v2.3, VEST 3.0, PolyPhen-2, SIFT, PROVEAN, MutationAssessor, MutationTaster, LRT, GERP++, SiPhy, phyloP, and phastCons. The REVEL score for an individual missense variant can range from 0 to 1, with higher scores reflecting greater likelihood that the variant is disease-causing. ClinVar has also classified this variant as Pathogenic, Likely Benign, and Conflicting Interpretations (Variant ID: 15333). This variant has previously been reported for sickle cell anemia by Jaripour ME, et, al., 2018. Experimental studies have shown that this missense change affects HBB function by Eshbach ML, et, al, 2017. Based on the above evidence this variant has been classified as Pathogenic according to the ACMG guidelines. (less)
Ethnicity/Population group: Asian
Geographic origin: India
|
|
Pathogenic
(-)
|
criteria provided, single submitter
Method: clinical testing
|
HBB-related disorders
Affected status: yes
Allele origin:
germline
|
Rady Children's Institute for Genomic Medicine, Rady Children's Hospital San Diego
Accession: SCV004046417.1
First in ClinVar: Oct 21, 2023 Last updated: Oct 21, 2023 |
Comment:
The c.20A>T (p.Glu7Val) variant in HBB, also known as p.Glu6Val, is referred to as the hemoglobin S allele (HbS) and causes autosomal recessive sickle cell … (more)
The c.20A>T (p.Glu7Val) variant in HBB, also known as p.Glu6Val, is referred to as the hemoglobin S allele (HbS) and causes autosomal recessive sickle cell disease (MIM: #603903) when it is homozygous or compound heterozygous with a different pathogenic variant. Individuals who are heterozygous for the HbS allele have sickle cell trait (SCT). The c.20A>T (p.Glu7Val) variant is the most prevalent genotype associated with sickle cell disease (PMID: 25203083). This variant affects a highly conserved amino acid and is predicted by multiple in silico tools to have a deleterious effect on protein function. It is present at a frequency of 0.4% (1236/282580 heterozygotes and 4/282580 homozygotes) in the gnomAD population database. The c.20A>T (p.Glu7Val) variant is an established disease-causing mutation. Based on the available evidence, c.20A>T(p.Glu7Val) is classified as Pathogenic. (less)
|
|
Pathogenic
(-)
|
criteria provided, single submitter
Method: clinical testing
|
Hb SS disease
(Autosomal recessive inheritance)
Affected status: yes
Allele origin:
germline
|
Neuberg Centre For Genomic Medicine, NCGM
Accession: SCV004048527.1
First in ClinVar: Oct 28, 2023 Last updated: Oct 28, 2023 |
Comment:
The missense c.20A>T (p.Glu7Val) variant in HBB has been reported in homozygous individuals affected with sickle cell anemia and heterozygous state in sickle cell anemia … (more)
The missense c.20A>T (p.Glu7Val) variant in HBB has been reported in homozygous individuals affected with sickle cell anemia and heterozygous state in sickle cell anemia trait. This is a common, well-known variant that has been observed in individuals affected with sickle cell disease (Kutlar, Ferdane et al.,2010 and Bender, MA.,2003). Experimental studies have shown that this missense change affects hemoglobin polymerization and can result in abnormally-shaped red blood cells (He, Zhenning et al.,2002, Eshbach, Megan L et al.,2017). This variant is reported with the allele frequency 0.4% in the gnomAD and 2.7% in 1000 genome database. It has been submitted to ClinVar as Pathogenic. The amino acid Glu at position 7 is changed to a Val changing protein sequence and it might alter its composition and physico-chemical properties. The variant is predicted to be damaging by SIFT and the residue is conserved across species. The amino acid change p.Glu7Val in HBB is predicted as conserved by GERP++ and PhyloP across 100 vertebrates. For these reasons, this variant has been classified as Pathogenic. (less)
Clinical Features:
Jaundice (present) , Hyperbilirubinemia (present)
|
|
Pathogenic
(Mar 25, 2024)
|
criteria provided, single submitter
Method: clinical testing
|
Malaria, susceptibility to
Affected status: unknown
Allele origin:
germline
|
Center for Genomic Medicine, King Faisal Specialist Hospital and Research Center
Accession: SCV004806248.1
First in ClinVar: Apr 06, 2024 Last updated: Apr 06, 2024 |
|
|
Pathogenic
(Oct 13, 2023)
|
criteria provided, single submitter
Method: clinical testing
|
Inborn genetic diseases
Affected status: unknown
Allele origin:
germline
|
Ambry Genetics
Accession: SCV000741189.3
First in ClinVar: Apr 15, 2018 Last updated: May 01, 2024 |
Comment:
The c.20A>T (p.E7V) alteration is located in exon 1 of the HBB gene. This alteration results from a A to T substitution at nucleotide position … (more)
The c.20A>T (p.E7V) alteration is located in exon 1 of the HBB gene. This alteration results from a A to T substitution at nucleotide position 20, causing the glutamic acid (E) at amino acid position 7 to be replaced by a valine (V). Based on data from gnomAD, the T allele has an overall frequency of 0.44% (1236/282580) total alleles studied. The highest observed frequency was 4.49% (1121/24964) of African/African American alleles. This alteration results in the hemoglobin S (HbS) variant and is associated with sickle cell disease (Ingram, 1956). This amino acid position is not well conserved in available vertebrate species. The p.E7V alteration is known to significantly decrease the solubility of the hemoglobin protein, allowing for the polymerization that ultimately results in red cell sickling (Adachi, 1987). The in silico prediction for this alteration is inconclusive. Based on the available evidence, this alteration is classified as pathogenic. (less)
|
|
Pathogenic
(Apr 22, 2024)
|
criteria provided, single submitter
Method: clinical testing
|
Hb SS disease
Affected status: unknown
Allele origin:
unknown
|
Genomic Research Center, Shahid Beheshti University of Medical Sciences
Accession: SCV004934109.1
First in ClinVar: May 01, 2024 Last updated: May 01, 2024 |
Sex: female
Geographic origin: Iran
|
|
Pathogenic
(Jul 31, 2024)
|
criteria provided, single submitter
Method: clinical testing
|
not provided
Affected status: unknown
Allele origin:
germline
|
Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital
Accession: SCV005090881.1
First in ClinVar: Aug 04, 2024 Last updated: Aug 04, 2024 |
|
|
Pathogenic
(May 17, 2023)
|
criteria provided, single submitter
Method: clinical testing
|
not provided
Affected status: yes
Allele origin:
germline
|
Clinical Genetics Laboratory, Skane University Hospital Lund
Accession: SCV005198430.1
First in ClinVar: Aug 25, 2024 Last updated: Aug 25, 2024 |
|
|
Pathogenic
(Aug 01, 2024)
|
criteria provided, single submitter
Method: clinical testing
|
not provided
Affected status: yes
Allele origin:
germline
|
CeGaT Center for Human Genetics Tuebingen
Accession: SCV002062958.20
First in ClinVar: Jan 29, 2022 Last updated: Oct 20, 2024 |
Comment:
HBB: PM3:Very Strong, PS3:Moderate, PM2:Supporting, PP4, BP4
Number of individuals with the variant: 6
|
|
Pathogenic
(Feb 23, 2016)
|
no assertion criteria provided
Method: research
|
Dominant beta-thalassemia
Hb SS disease Hereditary persistence of fetal hemoglobin Malaria, susceptibility to Beta-thalassemia HBB/LCRB Heinz body anemia
Affected status: unknown
Allele origin:
germline
|
Division of Human Genetics, Children's Hospital of Philadelphia
Study: CSER-PediSeq
Accession: SCV000536833.1 First in ClinVar: Apr 23, 2017 Last updated: Apr 23, 2017 |
|
|
Pathogenic
(Sep 16, 2018)
|
no assertion criteria provided
Method: research
|
not provided
Affected status: yes
Allele origin:
germline
|
Gharavi Laboratory, Columbia University
Accession: SCV000809296.1
First in ClinVar: Dec 19, 2017 Last updated: Dec 19, 2017 |
|
|
Pathogenic
(Jul 19, 2018)
|
no assertion criteria provided
Method: clinical testing
|
Hereditary persistence of fetal hemoglobin
Affected status: yes
Allele origin:
germline
|
Biochemical Molecular Genetic Laboratory, King Abdulaziz Medical City
Accession: SCV000854734.1
First in ClinVar: Dec 09, 2018 Last updated: Dec 09, 2018 |
|
|
Pathogenic
(-)
|
no assertion criteria provided
Method: clinical testing
|
not provided
Affected status: yes
Allele origin:
germline
|
Genome Diagnostics Laboratory, University Medical Center Utrecht
Additional submitter:
Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen
Study: VKGL Data-share Consensus
Accession: SCV001932948.1 First in ClinVar: Sep 26, 2021 Last updated: Sep 26, 2021 |
|
|
Pathogenic
(-)
|
no assertion criteria provided
Method: clinical testing
|
not provided
Affected status: yes
Allele origin:
germline
|
Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+
Additional submitter:
Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen
Study: VKGL Data-share Consensus
Accession: SCV001955042.1 First in ClinVar: Oct 02, 2021 Last updated: Oct 02, 2021 |
|
|
Pathogenic
(-)
|
no assertion criteria provided
Method: clinical testing
|
not provided
Affected status: yes
Allele origin:
germline
|
Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center
Additional submitter:
Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen
Study: VKGL Data-share Consensus
Accession: SCV001975550.1 First in ClinVar: Oct 08, 2021 Last updated: Oct 08, 2021 |
|
|
Pathogenic
(Jan 07, 2022)
|
no assertion criteria provided
Method: clinical testing
|
Hb SS disease
Affected status: yes
Allele origin:
germline
|
Genetic Services Laboratory, University of Chicago
Accession: SCV002064353.3
First in ClinVar: Jan 29, 2022 Last updated: Dec 11, 2022 |
|
|
Pathogenic
(-)
|
no assertion criteria provided
Method: research
|
Hb SS disease
Affected status: yes
Allele origin:
unknown
|
Genomics And Bioinformatics Analysis Resource, Columbia University
Accession: SCV004024078.1
First in ClinVar: Aug 13, 2023 Last updated: Aug 13, 2023
Comment:
Homozygous
|
|
|
Pathogenic
(Dec 02, 2011)
|
no assertion criteria provided
Method: literature only
|
SICKLE CELL DISEASE
Affected status: not provided
Allele origin:
germline
|
OMIM
Accession: SCV005046837.1
First in ClinVar: Jun 09, 2024 Last updated: Jun 09, 2024 |
Comment on evidence:
The change from glutamic acid to valine in sickle hemoglobin was reported by Ingram (1959). Ingram (1956) had reported that the difference between hemoglobin A … (more)
The change from glutamic acid to valine in sickle hemoglobin was reported by Ingram (1959). Ingram (1956) had reported that the difference between hemoglobin A and hemoglobin S lies in a single tryptic peptide. His analysis of this peptide, peptide 4, was possible by the methods developed by Sanger for determining the structure of insulin and Edman's stepwise degradation of peptides. Kan and Dozy (1978) used the HpaI restriction endonuclease polymorphism (actually the linkage principle) to make the prenatal diagnosis of sickle cell anemia (603903). As described in 143020, when 'normal' DNA is digested with HpaI, the beta-globin gene is contained in a fragment 7.6 kilobases long. In persons of African extraction 2 variants were detected, 7.0 kb and 13.0 kb long. These variants resulted from alteration in the normal HpaI recognition site 5000 nucleotides to the 3-prime side of the beta-globin gene. The 7.6 and 7.0 kb fragments were present in persons with Hb A, while 87% of persons with Hb S had the 13.0 kb variant. The method is sufficiently sensitive that the cells in 15 ml of uncultured amniotic fluid sufficed. Restriction enzyme studies indicate that whereas Hb S and Hb C originated against the same genetic background (as independent mutations) and the Hb S in the Mediterranean littoral probably is the same mutation as the West African Hb S, Hb S in Asia is apparently a separate mutation. It does not show association with the noncoding polymorphism (Kan and Dozy, 1979). Mears et al. (1981) used the linkage of the sickle gene with restriction polymorphisms to trace the origin of the sickle gene in Africa. They found evidence that 2 different chromosomes bearing sickle genes were subjected to selection and expansion in 2 physically close but ethnically separate regions of West Africa, with subsequent diffusion to other areas of Africa. The restriction enzyme MnlI recognizes the sequence G-A-G-G, which also is eliminated by the sickle mutation. The MstII enzyme recognizes the sequence C-C-T-N-A-G-G. Predictably, the resulting fragments are larger than those produced by some other enzymes, and MstII is, therefore, particularly useful in prenatal diagnosis (Wilson et al., 1982). The sickle cell mutation can be identified directly in DNA by use of either of 2 restriction endonucleases, DdeI or MstII (Geever et al., 1981; Kazazian, 1982). The nucleotide substitution alters a specific cleavage site recognized by each of these 2 enzymes. The fifth, sixth, and seventh codons of Hb A are CCT-GAG-GAG; in Hb S, they are CCT-GTG-GAG. The recognition site for DdeI is C-T-N-A-G, in which N = any nucleoside. Chang and Kan (1982) and Orkin et al. (1982) found that the assay using the restriction enzyme MstII is sufficiently sensitive that it can be applied to uncultured amniotic fluid cells. The enzyme DdeI requires that the amniotic cells be cultured to obtain enough DNA for the assay. Antonarakis et al. (1984) applied the Kazazian haplotype method to the study of the origin of the sickle mutation in Africans. Among 170 beta-S bearing chromosomes, 16 different haplotypes of polymorphic sites were found. The 3 most common beta-S haplotypes, accounting for 151 of the 170, were only rarely seen in chromosomes bearing the beta-A gene in these populations (6 out of 47). They suggested the occurrence of up to 4 independent mutations and/or interallelic gene conversions. By haplotype analysis of the beta-globin gene cluster in cases of Hb S in different parts of Africa, Pagnier et al. (1984) concluded that the sickle mutation arose at least 3 times on separate preexisting chromosomal haplotypes. The Hb S gene is closely linked to 3 different haplotypes of polymorphic endonuclease restriction sites in the beta-like gene cluster: one prevalent in Atlantic West Africa, another in central West Africa, and the last in Bantu-speaking Africa (equatorial, East, and southern Africa). Nagel et al. (1985) found hematologic differences between the first 2 types explicable probably by differences in fetal hemoglobin production. Ramsay and Jenkins (1987) found that 20 of 23 sickle-associated haplotypes in southern-African Bantu-speaking black subjects were the same as those found commonly in the Central African Republic, a finding providing the first convincing biologic evidence for the common ancestry of geographically widely separated speakers of languages belonging to the Bantu family. The 3 haplotypes seen with the beta-S gene in Africa are referred to as Senegal, Benin, and Bantu. The 'Bantu line' extends across the waist of Africa; south of the line, Bantu languages are spoken. Based on their study, Ramsay and Jenkins (1987) suggested that the sickle cell mutation arose only once in the Bantu speakers, presumably in their nuclear area of origin, before the Bantu expansion occurred about 2,000 years ago. In Yaounde, the capital city of Cameroon, Lapoumeroulie et al. (1992) observed a novel RFLP pattern in the study of beta-S chromosomes. This chromosome contained an A-gamma-T gene and the RFLP haplotype was different from all the other beta(S) chromosomes in both the 5-prime and 3-prime regions. All the carriers of this specific chromosome belonged to the Eton ethnic group and originated from the Sanaga river valley. Kulozik et al. (1986) found that the sickle gene in Saudi Arabia and on the west and east coasts of India exists in a haplotype not found in Africa. They concluded that the data are most consistent with an independent Asian origin of the sickle cell mutation. The distribution of the Asian beta-S-haplotype corresponded to the reported geographic distribution of a mild clinical phenotype of homozygous SS disease. Ragusa et al. (1988) found that the beta-S gene in Sicily is in linkage disequilibrium with the Benin haplotype, the same haplotype observed among sickle cell anemia patients from Central West Africa. In addition, this haplotype is either nonexistent or very rare among nonsickling Sicilian persons. They concluded that the beta-S gene was introduced into Sicily from North Africa and that the gene flow originated in Central West Africa, traveling north through historically well-defined trans-Saharan commercial routes. Zeng et al. (1994) indicated that 5 different haplotypes associated with Hb S had been described, 4 in Africa (Bantu, Benin, Senegal, and Cameroon) and 1 found in both India and Saudi Arabia (Chebloune et al., 1988). There is a correlation between disease severity and haplotype for at least the 2 extremes of severity: patients with the Indian/Arabian haplotype have the mildest course of disease, while those with the Bantu haplotype exhibit the most severe course. Nucleotide -530 is a binding site for a protein called BP1 (601911), which may be a repressor of the HBB gene. BP1 binds with the highest affinity to the Indian haplotype sequence and with the weakest affinity to the Bantu sequence, which might explain the differences in clinical course in these different population groups. Zeng et al. (1994) demonstrated the same sequence at -530 bp in patients with the Arabian haplotype as in Indian sickle cell anemia patients. This supports the idea of a common origin of the sickle cell mutation in individuals in India and Saudi Arabia. Sammarco et al. (1988) presented further strong evidence that the Hb S gene in Sicily was brought by North African populations, probably during the Muslim invasions. Currat et al. (2002) studied the genetic diversity of the beta-globin gene cluster in an ethnically well-defined population, the Mandenka from eastern Senegal. The absence of recent admixture and amalgamation in this population permitted application of population genetics methods to investigate the origin of the sickle cell mutation (Flint et al., 1993) and to estimate its age. The frequency of the sickle cell mutation in the Mandenka was estimated as 11.7%. The mutation was found strictly associated with the single Senegal haplotype. Approximately 600 bp of the upstream region of the beta-globin gene were sequenced for 94 chromosomes, showing the presence of 4 transversions, 5 transitions, and a composite microsatellite polymorphism. The sequence of 22 chromosomes carrying the sickle mutation was also identical to the previously defined Senegal haplotype, suggesting that the mutation is very recent. Maximum likelihood estimates of the age of the mutation using Monte Carlo simulations were 45 to 70 generations (1,350-2,100 years) for different demographic scenarios. Embury et al. (1987) described a new method for rapid prenatal diagnosis of sickle cell anemia by DNA analysis. The first step involved a 200,000-fold enzymatic amplification of the specific beta-globin DNA sequences suspected of carrying the sickle mutation. Next, a short radiolabelled synthetic DNA sequence homologous to normal beta-A-globin gene sequences is hybridized to the amplified target sequence. The hybrid duplexes are then digested sequentially with 2 restriction endonucleases. The presence of the beta-A or beta-S gene sequence in the amplified target DNA from the patient determines whether the beta-A hybridization probe anneals perfectly or with a single nucleotide mismatch. This difference affects the restriction enzyme digestion of the DNA and the size of the resulting radiolabelled digestion products which can be distinguished by electrophoresis followed by autoradiography. The method was sufficiently sensitive and rapid that same-day prenatal diagnosis using fetal DNA was possible. The same test could be applied to the diagnosis of hemoglobin C disease. Hemoglobin C (Georgetown) also sickles. See Herrick (1910), Sherman (1940), Neel (1949), Pauling et al. (1949), Allison (1954), Ingram (1956, 1957, 1959), Chang and Kan (1981), and Shalev et al. (1988). Barany (1991) described a new assay designed to detect single base substitutions using a thermostable enzyme similar to the DNA polymerase used in PCR. This enzyme, DNA ligase, specifically links adjacent oligonucleotides only when the nucleotides are perfectly base-paired at the junction. In the presence of a second set of adjacent oligonucleotides, complementary to the first set and the target, the oligonucleotide products may be exponentially amplified by thermal cycling of the ligation reaction. Because a single base mismatch precludes ligation and amplification, it will be easily distinguished. Barany (1991) demonstrated the utility of the method in discriminating between normal and sickle globin genotypes from 10 microliter blood samples. Prezant and Fischel-Ghodsian (1992) described a trapped-oligonucleotide nucleotide incorporation (TONI) assay for the screening of a mitochondrial polymorphism and also showed that it could distinguish the genotypes of hemoglobins A/C, A/A, A/S, and S/S. The method was considered particularly useful for diagnosing mutations that do not produce alterations detectable by restriction enzyme analysis. It also requires only a single oligonucleotide and no electrophoretic separation of the allele-specific products. It represents an improved and simplified modification of the allele-specific primer extension methods. (TONI, the acronym for the method, is also the given name of the first author.) Grosveld et al. (1987) identified dominant control region (DCR) sequences that flank the human beta-globin locus and direct high-level, copy-number-dependent expression of the human beta-globin gene in erythroid cells in transgenic mice. By inserting a construct that included 2 human alpha genes and the defective human beta-sickle gene, all driven by the DCR sequences, Greaves et al. (1990) produced 2 mice with relatively high levels of human Hb S in their red cells. Use of this as an animal model for the study of this disease was suggested. Turhan et al. (2002) presented evidence suggesting that a pathogenetic mechanism in sickle cell vasoocclusion may reside in adherent leukocytes. Using intravital microscopy in mice expressing human sickle hemoglobin, they demonstrated that SS red blood cells bind to adherent leukocytes in inflamed venules, producing vasoocclusion of cremasteric venules. SS mice deficient in P- and E-selectins, which display defective leukocyte recruitment to the vessel wall, were protected from vasoocclusion. Thus, drugs targeting SS RBC-leukocyte or leukocyte-endothelial interactions might prevent or treat the vascular complications of this disease. Nitric oxide (NO), essential for maintaining vascular tone, is produced from arginine by NO synthase. Plasma arginine levels are low in sickle cell anemia, and Romero et al. (2002) reported that the sickle transgenic mouse model has low plasma arginine. They supplemented these mice with a 4-fold increase in arginine over a period of several months. Mean corpuscular hemoglobin concentration decreased and the percent high-density red cells was reduced. Romero et al. (2002) concluded that the major mechanism by which arginine supplementation reduces red cell density in these mice is by inhibiting the Ca(++)-activated K(+) channel. In a Jamaican study, Serjeant et al. (1968) described 60 patients with homozygous sickle cell disease who were 30 years of age or older, and Platt et al. (1994) estimated a median survival of 42 to 48 years. Serjeant et al. (2007) stated that the sickle cell clinic at the University of West Indies had treated 102 patients (64.7% women) who survived beyond their 60th birthday. None of the patients received hydroxyurea, and only 2 patients with renal impairment received regular transfusions. The ages of the patients ranged from 60.2 to 85.6 years. Measurement of fetal hemoglobin levels suggested that higher fetal hemoglobin levels probably conferred protection in childhood. The major clinical problems emerging with age were renal impairment and decreased levels of hemoglobin. Kwiatkowski (2005) noted that HbS homozygotes have sickle-cell disease, whereas heterozygosity confers a 10-fold increase in protection from life-threatening malaria (611162) and lesser protection against mild malaria. Cholera et al. (2008) found that P. falciparum (Pf)-infected HbA/HbS erythrocytes did not bind to microvascular endothelial cells as well as Pf-infected HbA/HbA erythrocytes. Reduced binding correlated with altered display of the major Pf cytoadherence ligand on erythrocyte membranes. Cholera et al. (2008) noted that this protective mechanism had features in common with that of HbC (141900.0038), and they suggested that weakening of cytoadherence interactions may influence the degree of malaria protection in HbA/HbS children. Modiano et al. (2008) adopted 2 partially independent haplotypic approaches to study the Mossi population in Burkina Faso, where both the HbS and HbC alleles are common. They showed that both alleles are monophyletic, but that the HbC allele has acquired higher recombinatorial and DNA slippage haplotypic variability or linkage disequilibrium decay and is likely older than HbS. Modiano et al. (2008) inferred that the HbC allele has accumulated mainly through recessive rather than a semidominant mechanism of selection. Gouagna et al. (2010) used cross-sectional surveys of 3,739 human subjects and transmission experiments involving 60 children and over 6,000 mosquitoes in Burkina Faso, West Africa, to test whether the HBB variants HbC and HbS, which are protective against malaria, are associated with transmission of the parasite from the human host to the Anopheles mosquito vector. They found that HbC and HbS were associated with significant 2-fold in vivo (P = 1.0 x 10(-6)) and 4-fold ex vivo (P = 7.0 x 10(-5)) increases of parasite transmission from host to vector. In addition, mean oocyte densities were particularly high in mosquitoes fed from HbS carriers. Ferreira et al. (2011) demonstrated that wildtype mice or mice expressing normal human Hb, but not mice expressing Hbs, developed experimental cerebral malaria (ECM) 6 to 12 days after infection with the murine malaria parasite, Plasmodium berghei. The Hbs mice eventually succumbed to the unrelated condition of hyperparasitemia-induced anemia. Tolerance to Plasmodium infection was associated with high levels of Hmox1 (141250) expression in hematopoietic cells, and mice expressing Hbs became susceptible to ECM when Hmox1 expression was inhibited. Hbs induced expression of Hmox1 in an Nrf2 (NFE2L2; 600492)-dependent manner, which inhibited the production of chemokines and Cd8-positive T cells associated with ECM pathogenesis. Ferreira et al. (2011) concluded that sickle hemoglobin suppresses the onset of ECM via induction of HMOX1 and the production of carbon monoxide, which inhibits the accumulation of free heme, affording tolerance to Plasmodium infection. Cyrklaff et al. (2011) found that HbS and HbC affect the trafficking system that directs parasite-encoded proteins to the surface of infected erythrocytes. Cryoelectron tomography revealed that P. falciparum generates a host-derived actin cytoskeleton within the cytoplasm of wildtype red blood cells that connects the Maurer clefts with the host cell membrane and to which transport vesicles are attached. The actin cytoskeleton and the Maurer clefts were aberrant in erythrocytes containing HbS or HbC. Hemoglobin oxidation products, enriched in HbS and HbC erythrocytes, inhibited actin polymerization in vitro and may account for the protective role in malaria. (less)
|
|
protective
(Dec 02, 2011)
|
no assertion criteria provided
Method: literature only
|
MALARIA, RESISTANCE TO
Affected status: not provided
Allele origin:
germline
|
OMIM
Accession: SCV000036844.11
First in ClinVar: Apr 04, 2013 Last updated: Jun 09, 2024 |
Comment on evidence:
The change from glutamic acid to valine in sickle hemoglobin was reported by Ingram (1959). Ingram (1956) had reported that the difference between hemoglobin A … (more)
The change from glutamic acid to valine in sickle hemoglobin was reported by Ingram (1959). Ingram (1956) had reported that the difference between hemoglobin A and hemoglobin S lies in a single tryptic peptide. His analysis of this peptide, peptide 4, was possible by the methods developed by Sanger for determining the structure of insulin and Edman's stepwise degradation of peptides. Kan and Dozy (1978) used the HpaI restriction endonuclease polymorphism (actually the linkage principle) to make the prenatal diagnosis of sickle cell anemia (603903). As described in 143020, when 'normal' DNA is digested with HpaI, the beta-globin gene is contained in a fragment 7.6 kilobases long. In persons of African extraction 2 variants were detected, 7.0 kb and 13.0 kb long. These variants resulted from alteration in the normal HpaI recognition site 5000 nucleotides to the 3-prime side of the beta-globin gene. The 7.6 and 7.0 kb fragments were present in persons with Hb A, while 87% of persons with Hb S had the 13.0 kb variant. The method is sufficiently sensitive that the cells in 15 ml of uncultured amniotic fluid sufficed. Restriction enzyme studies indicate that whereas Hb S and Hb C originated against the same genetic background (as independent mutations) and the Hb S in the Mediterranean littoral probably is the same mutation as the West African Hb S, Hb S in Asia is apparently a separate mutation. It does not show association with the noncoding polymorphism (Kan and Dozy, 1979). Mears et al. (1981) used the linkage of the sickle gene with restriction polymorphisms to trace the origin of the sickle gene in Africa. They found evidence that 2 different chromosomes bearing sickle genes were subjected to selection and expansion in 2 physically close but ethnically separate regions of West Africa, with subsequent diffusion to other areas of Africa. The restriction enzyme MnlI recognizes the sequence G-A-G-G, which also is eliminated by the sickle mutation. The MstII enzyme recognizes the sequence C-C-T-N-A-G-G. Predictably, the resulting fragments are larger than those produced by some other enzymes, and MstII is, therefore, particularly useful in prenatal diagnosis (Wilson et al., 1982). The sickle cell mutation can be identified directly in DNA by use of either of 2 restriction endonucleases, DdeI or MstII (Geever et al., 1981; Kazazian, 1982). The nucleotide substitution alters a specific cleavage site recognized by each of these 2 enzymes. The fifth, sixth, and seventh codons of Hb A are CCT-GAG-GAG; in Hb S, they are CCT-GTG-GAG. The recognition site for DdeI is C-T-N-A-G, in which N = any nucleoside. Chang and Kan (1982) and Orkin et al. (1982) found that the assay using the restriction enzyme MstII is sufficiently sensitive that it can be applied to uncultured amniotic fluid cells. The enzyme DdeI requires that the amniotic cells be cultured to obtain enough DNA for the assay. Antonarakis et al. (1984) applied the Kazazian haplotype method to the study of the origin of the sickle mutation in Africans. Among 170 beta-S bearing chromosomes, 16 different haplotypes of polymorphic sites were found. The 3 most common beta-S haplotypes, accounting for 151 of the 170, were only rarely seen in chromosomes bearing the beta-A gene in these populations (6 out of 47). They suggested the occurrence of up to 4 independent mutations and/or interallelic gene conversions. By haplotype analysis of the beta-globin gene cluster in cases of Hb S in different parts of Africa, Pagnier et al. (1984) concluded that the sickle mutation arose at least 3 times on separate preexisting chromosomal haplotypes. The Hb S gene is closely linked to 3 different haplotypes of polymorphic endonuclease restriction sites in the beta-like gene cluster: one prevalent in Atlantic West Africa, another in central West Africa, and the last in Bantu-speaking Africa (equatorial, East, and southern Africa). Nagel et al. (1985) found hematologic differences between the first 2 types explicable probably by differences in fetal hemoglobin production. Ramsay and Jenkins (1987) found that 20 of 23 sickle-associated haplotypes in southern-African Bantu-speaking black subjects were the same as those found commonly in the Central African Republic, a finding providing the first convincing biologic evidence for the common ancestry of geographically widely separated speakers of languages belonging to the Bantu family. The 3 haplotypes seen with the beta-S gene in Africa are referred to as Senegal, Benin, and Bantu. The 'Bantu line' extends across the waist of Africa; south of the line, Bantu languages are spoken. Based on their study, Ramsay and Jenkins (1987) suggested that the sickle cell mutation arose only once in the Bantu speakers, presumably in their nuclear area of origin, before the Bantu expansion occurred about 2,000 years ago. In Yaounde, the capital city of Cameroon, Lapoumeroulie et al. (1992) observed a novel RFLP pattern in the study of beta-S chromosomes. This chromosome contained an A-gamma-T gene and the RFLP haplotype was different from all the other beta(S) chromosomes in both the 5-prime and 3-prime regions. All the carriers of this specific chromosome belonged to the Eton ethnic group and originated from the Sanaga river valley. Kulozik et al. (1986) found that the sickle gene in Saudi Arabia and on the west and east coasts of India exists in a haplotype not found in Africa. They concluded that the data are most consistent with an independent Asian origin of the sickle cell mutation. The distribution of the Asian beta-S-haplotype corresponded to the reported geographic distribution of a mild clinical phenotype of homozygous SS disease. Ragusa et al. (1988) found that the beta-S gene in Sicily is in linkage disequilibrium with the Benin haplotype, the same haplotype observed among sickle cell anemia patients from Central West Africa. In addition, this haplotype is either nonexistent or very rare among nonsickling Sicilian persons. They concluded that the beta-S gene was introduced into Sicily from North Africa and that the gene flow originated in Central West Africa, traveling north through historically well-defined trans-Saharan commercial routes. Zeng et al. (1994) indicated that 5 different haplotypes associated with Hb S had been described, 4 in Africa (Bantu, Benin, Senegal, and Cameroon) and 1 found in both India and Saudi Arabia (Chebloune et al., 1988). There is a correlation between disease severity and haplotype for at least the 2 extremes of severity: patients with the Indian/Arabian haplotype have the mildest course of disease, while those with the Bantu haplotype exhibit the most severe course. Nucleotide -530 is a binding site for a protein called BP1 (601911), which may be a repressor of the HBB gene. BP1 binds with the highest affinity to the Indian haplotype sequence and with the weakest affinity to the Bantu sequence, which might explain the differences in clinical course in these different population groups. Zeng et al. (1994) demonstrated the same sequence at -530 bp in patients with the Arabian haplotype as in Indian sickle cell anemia patients. This supports the idea of a common origin of the sickle cell mutation in individuals in India and Saudi Arabia. Sammarco et al. (1988) presented further strong evidence that the Hb S gene in Sicily was brought by North African populations, probably during the Muslim invasions. Currat et al. (2002) studied the genetic diversity of the beta-globin gene cluster in an ethnically well-defined population, the Mandenka from eastern Senegal. The absence of recent admixture and amalgamation in this population permitted application of population genetics methods to investigate the origin of the sickle cell mutation (Flint et al., 1993) and to estimate its age. The frequency of the sickle cell mutation in the Mandenka was estimated as 11.7%. The mutation was found strictly associated with the single Senegal haplotype. Approximately 600 bp of the upstream region of the beta-globin gene were sequenced for 94 chromosomes, showing the presence of 4 transversions, 5 transitions, and a composite microsatellite polymorphism. The sequence of 22 chromosomes carrying the sickle mutation was also identical to the previously defined Senegal haplotype, suggesting that the mutation is very recent. Maximum likelihood estimates of the age of the mutation using Monte Carlo simulations were 45 to 70 generations (1,350-2,100 years) for different demographic scenarios. Embury et al. (1987) described a new method for rapid prenatal diagnosis of sickle cell anemia by DNA analysis. The first step involved a 200,000-fold enzymatic amplification of the specific beta-globin DNA sequences suspected of carrying the sickle mutation. Next, a short radiolabelled synthetic DNA sequence homologous to normal beta-A-globin gene sequences is hybridized to the amplified target sequence. The hybrid duplexes are then digested sequentially with 2 restriction endonucleases. The presence of the beta-A or beta-S gene sequence in the amplified target DNA from the patient determines whether the beta-A hybridization probe anneals perfectly or with a single nucleotide mismatch. This difference affects the restriction enzyme digestion of the DNA and the size of the resulting radiolabelled digestion products which can be distinguished by electrophoresis followed by autoradiography. The method was sufficiently sensitive and rapid that same-day prenatal diagnosis using fetal DNA was possible. The same test could be applied to the diagnosis of hemoglobin C disease. Hemoglobin C (Georgetown) also sickles. See Herrick (1910), Sherman (1940), Neel (1949), Pauling et al. (1949), Allison (1954), Ingram (1956, 1957, 1959), Chang and Kan (1981), and Shalev et al. (1988). Barany (1991) described a new assay designed to detect single base substitutions using a thermostable enzyme similar to the DNA polymerase used in PCR. This enzyme, DNA ligase, specifically links adjacent oligonucleotides only when the nucleotides are perfectly base-paired at the junction. In the presence of a second set of adjacent oligonucleotides, complementary to the first set and the target, the oligonucleotide products may be exponentially amplified by thermal cycling of the ligation reaction. Because a single base mismatch precludes ligation and amplification, it will be easily distinguished. Barany (1991) demonstrated the utility of the method in discriminating between normal and sickle globin genotypes from 10 microliter blood samples. Prezant and Fischel-Ghodsian (1992) described a trapped-oligonucleotide nucleotide incorporation (TONI) assay for the screening of a mitochondrial polymorphism and also showed that it could distinguish the genotypes of hemoglobins A/C, A/A, A/S, and S/S. The method was considered particularly useful for diagnosing mutations that do not produce alterations detectable by restriction enzyme analysis. It also requires only a single oligonucleotide and no electrophoretic separation of the allele-specific products. It represents an improved and simplified modification of the allele-specific primer extension methods. (TONI, the acronym for the method, is also the given name of the first author.) Grosveld et al. (1987) identified dominant control region (DCR) sequences that flank the human beta-globin locus and direct high-level, copy-number-dependent expression of the human beta-globin gene in erythroid cells in transgenic mice. By inserting a construct that included 2 human alpha genes and the defective human beta-sickle gene, all driven by the DCR sequences, Greaves et al. (1990) produced 2 mice with relatively high levels of human Hb S in their red cells. Use of this as an animal model for the study of this disease was suggested. Turhan et al. (2002) presented evidence suggesting that a pathogenetic mechanism in sickle cell vasoocclusion may reside in adherent leukocytes. Using intravital microscopy in mice expressing human sickle hemoglobin, they demonstrated that SS red blood cells bind to adherent leukocytes in inflamed venules, producing vasoocclusion of cremasteric venules. SS mice deficient in P- and E-selectins, which display defective leukocyte recruitment to the vessel wall, were protected from vasoocclusion. Thus, drugs targeting SS RBC-leukocyte or leukocyte-endothelial interactions might prevent or treat the vascular complications of this disease. Nitric oxide (NO), essential for maintaining vascular tone, is produced from arginine by NO synthase. Plasma arginine levels are low in sickle cell anemia, and Romero et al. (2002) reported that the sickle transgenic mouse model has low plasma arginine. They supplemented these mice with a 4-fold increase in arginine over a period of several months. Mean corpuscular hemoglobin concentration decreased and the percent high-density red cells was reduced. Romero et al. (2002) concluded that the major mechanism by which arginine supplementation reduces red cell density in these mice is by inhibiting the Ca(++)-activated K(+) channel. In a Jamaican study, Serjeant et al. (1968) described 60 patients with homozygous sickle cell disease who were 30 years of age or older, and Platt et al. (1994) estimated a median survival of 42 to 48 years. Serjeant et al. (2007) stated that the sickle cell clinic at the University of West Indies had treated 102 patients (64.7% women) who survived beyond their 60th birthday. None of the patients received hydroxyurea, and only 2 patients with renal impairment received regular transfusions. The ages of the patients ranged from 60.2 to 85.6 years. Measurement of fetal hemoglobin levels suggested that higher fetal hemoglobin levels probably conferred protection in childhood. The major clinical problems emerging with age were renal impairment and decreased levels of hemoglobin. Kwiatkowski (2005) noted that HbS homozygotes have sickle-cell disease, whereas heterozygosity confers a 10-fold increase in protection from life-threatening malaria (611162) and lesser protection against mild malaria. Cholera et al. (2008) found that P. falciparum (Pf)-infected HbA/HbS erythrocytes did not bind to microvascular endothelial cells as well as Pf-infected HbA/HbA erythrocytes. Reduced binding correlated with altered display of the major Pf cytoadherence ligand on erythrocyte membranes. Cholera et al. (2008) noted that this protective mechanism had features in common with that of HbC (141900.0038), and they suggested that weakening of cytoadherence interactions may influence the degree of malaria protection in HbA/HbS children. Modiano et al. (2008) adopted 2 partially independent haplotypic approaches to study the Mossi population in Burkina Faso, where both the HbS and HbC alleles are common. They showed that both alleles are monophyletic, but that the HbC allele has acquired higher recombinatorial and DNA slippage haplotypic variability or linkage disequilibrium decay and is likely older than HbS. Modiano et al. (2008) inferred that the HbC allele has accumulated mainly through recessive rather than a semidominant mechanism of selection. Gouagna et al. (2010) used cross-sectional surveys of 3,739 human subjects and transmission experiments involving 60 children and over 6,000 mosquitoes in Burkina Faso, West Africa, to test whether the HBB variants HbC and HbS, which are protective against malaria, are associated with transmission of the parasite from the human host to the Anopheles mosquito vector. They found that HbC and HbS were associated with significant 2-fold in vivo (P = 1.0 x 10(-6)) and 4-fold ex vivo (P = 7.0 x 10(-5)) increases of parasite transmission from host to vector. In addition, mean oocyte densities were particularly high in mosquitoes fed from HbS carriers. Ferreira et al. (2011) demonstrated that wildtype mice or mice expressing normal human Hb, but not mice expressing Hbs, developed experimental cerebral malaria (ECM) 6 to 12 days after infection with the murine malaria parasite, Plasmodium berghei. The Hbs mice eventually succumbed to the unrelated condition of hyperparasitemia-induced anemia. Tolerance to Plasmodium infection was associated with high levels of Hmox1 (141250) expression in hematopoietic cells, and mice expressing Hbs became susceptible to ECM when Hmox1 expression was inhibited. Hbs induced expression of Hmox1 in an Nrf2 (NFE2L2; 600492)-dependent manner, which inhibited the production of chemokines and Cd8-positive T cells associated with ECM pathogenesis. Ferreira et al. (2011) concluded that sickle hemoglobin suppresses the onset of ECM via induction of HMOX1 and the production of carbon monoxide, which inhibits the accumulation of free heme, affording tolerance to Plasmodium infection. Cyrklaff et al. (2011) found that HbS and HbC affect the trafficking system that directs parasite-encoded proteins to the surface of infected erythrocytes. Cryoelectron tomography revealed that P. falciparum generates a host-derived actin cytoskeleton within the cytoplasm of wildtype red blood cells that connects the Maurer clefts with the host cell membrane and to which transport vesicles are attached. The actin cytoskeleton and the Maurer clefts were aberrant in erythrocytes containing HbS or HbC. Hemoglobin oxidation products, enriched in HbS and HbC erythrocytes, inhibited actin polymerization in vitro and may account for the protective role in malaria. (less)
|
|
Pathogenic
(May 07, 2024)
|
no assertion criteria provided
Method: clinical testing
|
Beta-thalassemia HBB/LCRB
Affected status: yes
Allele origin:
germline
|
MOLECULAR BIOLOGY AND HUMAN GENETICS DIVISION, THE UNIVERSITY OF BURDWAN
Accession: SCV005196600.1
First in ClinVar: Aug 25, 2024 Last updated: Aug 25, 2024 |
Comment:
The variant HBB:c.20A>T [NP_000509.1:p.Glu7Val ] , produce sickle hemoglobin (HbS), it is a beta+ mutation. Homozygous of this variant is responsible for sickle cell anaemia … (more)
The variant HBB:c.20A>T [NP_000509.1:p.Glu7Val ] , produce sickle hemoglobin (HbS), it is a beta+ mutation. Homozygous of this variant is responsible for sickle cell anaemia . In combination with other beta mutation it may cause wide variety of sickle beta phenotype. The frequency of this allele in different state of India varies from 2 % to 20% (Ref: PMID: 30523337] . The frequency of this variant among hemoglobinopathy patient in West Bengal is less than 3.8 % as per multicentric project - A Genetic Diagnostic Algorithm Based Study for Thalassemia in Northern and Eastern Indian Populations, Funded by Dept. of Biotechnology , Govt of India [Project No. BT/PR26461/MED/12/821/2018]. (less)
Number of individuals with the variant: 39
Sex: mixed
Ethnicity/Population group: Southeast Asian
Geographic origin: India
|
|
Pathogenic
(Jul 30, 2024)
|
no assertion criteria provided
Method: clinical testing
|
HBB-related condition
Affected status: unknown
Allele origin:
germline
|
PreventionGenetics, part of Exact Sciences
Accession: SCV004113642.3
First in ClinVar: Nov 20, 2023 Last updated: Oct 08, 2024 |
Comment:
The HBB c.20A>T variant is predicted to result in the amino acid substitution p.Glu7Val. This variant, also referred to as p.Glu6Val using legacy nomenclature, has … (more)
The HBB c.20A>T variant is predicted to result in the amino acid substitution p.Glu7Val. This variant, also referred to as p.Glu6Val using legacy nomenclature, has previously been reported to be causative for sickle cell anemia when present in the homozygous state (Engelke et al. 1988. PubMed ID: 3267215; Bender et al. 2017. PubMed ID: 20301551). Individuals heterozygous for this variant have sickle cell trait and are usually asymptomatic but can be at risk for complications, including exertional rhabdomyolysis, pulmonary emboli, and sudden death with extreme exertion (Key and Derebail. 2010. PubMed ID: 21239829; Bender et al. 2023. PubMed ID: 20301551). This variant is reported in 4.5% of alleles in individuals of African descent in gnomAD. We interpret this variant as pathogenic. (less)
|
|
Pathogenic
(Jan 06, 2020)
|
no assertion criteria provided
Method: curation
|
Beta-thalassemia
Affected status: unknown
Allele origin:
germline
|
Reproductive Health Research and Development, BGI Genomics
Accession: SCV001142414.1
First in ClinVar: Jan 13, 2020 Last updated: Jan 13, 2020 |
Comment:
NM_000518.4:c.20A>T is also known as p.Glu6Lys or HbS in the literature. NM_000518.4:c.20A>T in the HBB gene has an allele frequency of 0.045 in African subpopulation … (more)
NM_000518.4:c.20A>T is also known as p.Glu6Lys or HbS in the literature. NM_000518.4:c.20A>T in the HBB gene has an allele frequency of 0.045 in African subpopulation in the gnomAD database. The c.20A>T (p.Glu7Val) variant in HBB is the most prevalent genotype associated with sickle cell disease (PMID: 25203083). Kondani et al reported that among 247 children, 19 (7.7%) were homozygous sickle cell anemia patients (Hb SS) (PMID: 25023084). Experimental studies have shown that this missense change affects hemoglobin polymerization and can result in abnormally-shaped red blood cells (PMID: 12124399; 28356267; 1802884). Taken together, we interprete this variant as Pathogenic/Likely pathogenic. ACMG/AMP Criteria applied: PS4; PS3; PM3; PP4. (less)
|
|
Pathogenic
(Jan 16, 2020)
|
no assertion criteria provided
Method: clinical testing
|
Anemia
Affected status: yes
Allele origin:
germline
|
New York Genome Center
Accession: SCV001431215.2
First in ClinVar: Sep 05, 2020 Last updated: Sep 05, 2020 |
Secondary finding: no
Method: whole genome sequencing
|
|
Pathogenic
(-)
|
no assertion criteria provided
Method: clinical testing
|
not provided
Affected status: yes
Allele origin:
germline
|
Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen
Study: VKGL Data-share Consensus
Accession: SCV001743401.3 First in ClinVar: Jul 07, 2021 Last updated: Sep 08, 2021 |
|
|
Pathogenic
(Mar 17, 2017)
|
no assertion criteria provided
Method: clinical testing
|
Beta thalassemia
Affected status: unknown
Allele origin:
germline
|
Natera, Inc.
Accession: SCV002091614.1
First in ClinVar: Apr 23, 2022 Last updated: Apr 23, 2022 |
|
|
not provided
(-)
|
no classification provided
Method: literature only
|
Hb SS disease
Affected status: unknown
Allele origin:
germline
|
GeneReviews
Accession: SCV000190688.3
First in ClinVar: Oct 05, 2015 Last updated: Oct 01, 2022 |
|
|
not provided
(-)
|
no classification provided
Method: phenotyping only
|
beta Thalassemia
Affected status: unknown
Allele origin:
paternal
|
GenomeConnect - Brain Gene Registry
Accession: SCV003931163.1
First in ClinVar: Jun 17, 2023 Last updated: Jun 17, 2023 |
Comment:
Variant classified as Pathogenic and reported on 02-03-2017 by Baylor Medical Genetics Laboratories. Assertions are reported exactly as they appear on the patient provided laboratory … (more)
Variant classified as Pathogenic and reported on 02-03-2017 by Baylor Medical Genetics Laboratories. Assertions are reported exactly as they appear on the patient provided laboratory report. GenomeConnect does not attempt to reinterpret the variant. The IDDRC-CTSA National Brain Gene Registry (BGR) is a study funded by the U.S. National Center for Advancing Translational Sciences (NCATS) and includes 13 Intellectual and Developmental Disability Research Center (IDDRC) institutions. The study is led by Principal Investigator Dr. Philip Payne from Washington University. The BGR is a data commons of gene variants paired with subject clinical information. This database helps scientists learn more about genetic changes and their impact on the brain and behavior. Participation in the Brain Gene Registry requires participation in GenomeConnect. More information about the Brain Gene Registry can be found on the study website - https://braingeneregistry.wustl.edu/. (less)
Clinical Features:
Recurrent streptococcal infections (present) , Delayed speech and language development (present) , Intellectual disability (present) , Abnormal facial shape (present)
Indication for testing: Diagnostic
Age: 10-19 years
Sex: male
Method: Exome Sequencing
Testing laboratory: Baylor Genetics
Date variant was reported to submitter: 2017-02-03
Testing laboratory interpretation: Pathogenic
|
|
not provided
(Sep 15, 2023)
|
no classification provided
Method: literature only
|
HEMOGLOBIN S
Affected status: not provided
Allele origin:
germline
|
OMIM
Accession: SCV000036842.14
First in ClinVar: Apr 04, 2013 Last updated: Jun 09, 2024 |
Comment on evidence:
The change from glutamic acid to valine in sickle hemoglobin was reported by Ingram (1959). Ingram (1956) had reported that the difference between hemoglobin A … (more)
The change from glutamic acid to valine in sickle hemoglobin was reported by Ingram (1959). Ingram (1956) had reported that the difference between hemoglobin A and hemoglobin S lies in a single tryptic peptide. His analysis of this peptide, peptide 4, was possible by the methods developed by Sanger for determining the structure of insulin and Edman's stepwise degradation of peptides. Kan and Dozy (1978) used the HpaI restriction endonuclease polymorphism (actually the linkage principle) to make the prenatal diagnosis of sickle cell anemia (603903). As described in 143020, when 'normal' DNA is digested with HpaI, the beta-globin gene is contained in a fragment 7.6 kilobases long. In persons of African extraction 2 variants were detected, 7.0 kb and 13.0 kb long. These variants resulted from alteration in the normal HpaI recognition site 5000 nucleotides to the 3-prime side of the beta-globin gene. The 7.6 and 7.0 kb fragments were present in persons with Hb A, while 87% of persons with Hb S had the 13.0 kb variant. The method is sufficiently sensitive that the cells in 15 ml of uncultured amniotic fluid sufficed. Restriction enzyme studies indicate that whereas Hb S and Hb C originated against the same genetic background (as independent mutations) and the Hb S in the Mediterranean littoral probably is the same mutation as the West African Hb S, Hb S in Asia is apparently a separate mutation. It does not show association with the noncoding polymorphism (Kan and Dozy, 1979). Mears et al. (1981) used the linkage of the sickle gene with restriction polymorphisms to trace the origin of the sickle gene in Africa. They found evidence that 2 different chromosomes bearing sickle genes were subjected to selection and expansion in 2 physically close but ethnically separate regions of West Africa, with subsequent diffusion to other areas of Africa. The restriction enzyme MnlI recognizes the sequence G-A-G-G, which also is eliminated by the sickle mutation. The MstII enzyme recognizes the sequence C-C-T-N-A-G-G. Predictably, the resulting fragments are larger than those produced by some other enzymes, and MstII is, therefore, particularly useful in prenatal diagnosis (Wilson et al., 1982). The sickle cell mutation can be identified directly in DNA by use of either of 2 restriction endonucleases, DdeI or MstII (Geever et al., 1981; Kazazian, 1982). The nucleotide substitution alters a specific cleavage site recognized by each of these 2 enzymes. The fifth, sixth, and seventh codons of Hb A are CCT-GAG-GAG; in Hb S, they are CCT-GTG-GAG. The recognition site for DdeI is C-T-N-A-G, in which N = any nucleoside. Chang and Kan (1982) and Orkin et al. (1982) found that the assay using the restriction enzyme MstII is sufficiently sensitive that it can be applied to uncultured amniotic fluid cells. The enzyme DdeI requires that the amniotic cells be cultured to obtain enough DNA for the assay. Antonarakis et al. (1984) applied the Kazazian haplotype method to the study of the origin of the sickle mutation in Africans. Among 170 beta-S bearing chromosomes, 16 different haplotypes of polymorphic sites were found. The 3 most common beta-S haplotypes, accounting for 151 of the 170, were only rarely seen in chromosomes bearing the beta-A gene in these populations (6 out of 47). They suggested the occurrence of up to 4 independent mutations and/or interallelic gene conversions. By haplotype analysis of the beta-globin gene cluster in cases of Hb S in different parts of Africa, Pagnier et al. (1984) concluded that the sickle mutation arose at least 3 times on separate preexisting chromosomal haplotypes. The Hb S gene is closely linked to 3 different haplotypes of polymorphic endonuclease restriction sites in the beta-like gene cluster: one prevalent in Atlantic West Africa, another in central West Africa, and the last in Bantu-speaking Africa (equatorial, East, and southern Africa). Nagel et al. (1985) found hematologic differences between the first 2 types explicable probably by differences in fetal hemoglobin production. Ramsay and Jenkins (1987) found that 20 of 23 sickle-associated haplotypes in southern-African Bantu-speaking black subjects were the same as those found commonly in the Central African Republic, a finding providing the first convincing biologic evidence for the common ancestry of geographically widely separated speakers of languages belonging to the Bantu family. The 3 haplotypes seen with the beta-S gene in Africa are referred to as Senegal, Benin, and Bantu. The 'Bantu line' extends across the waist of Africa; south of the line, Bantu languages are spoken. Based on their study, Ramsay and Jenkins (1987) suggested that the sickle cell mutation arose only once in the Bantu speakers, presumably in their nuclear area of origin, before the Bantu expansion occurred about 2,000 years ago. In Yaounde, the capital city of Cameroon, Lapoumeroulie et al. (1992) observed a novel RFLP pattern in the study of beta-S chromosomes. This chromosome contained an A-gamma-T gene and the RFLP haplotype was different from all the other beta(S) chromosomes in both the 5-prime and 3-prime regions. All the carriers of this specific chromosome belonged to the Eton ethnic group and originated from the Sanaga river valley. Kulozik et al. (1986) found that the sickle gene in Saudi Arabia and on the west and east coasts of India exists in a haplotype not found in Africa. They concluded that the data are most consistent with an independent Asian origin of the sickle cell mutation. The distribution of the Asian beta-S-haplotype corresponded to the reported geographic distribution of a mild clinical phenotype of homozygous SS disease. Ragusa et al. (1988) found that the beta-S gene in Sicily is in linkage disequilibrium with the Benin haplotype, the same haplotype observed among sickle cell anemia patients from Central West Africa. In addition, this haplotype is either nonexistent or very rare among nonsickling Sicilian persons. They concluded that the beta-S gene was introduced into Sicily from North Africa and that the gene flow originated in Central West Africa, traveling north through historically well-defined trans-Saharan commercial routes. Zeng et al. (1994) indicated that 5 different haplotypes associated with Hb S had been described, 4 in Africa (Bantu, Benin, Senegal, and Cameroon) and 1 found in both India and Saudi Arabia (Chebloune et al., 1988). There is a correlation between disease severity and haplotype for at least the 2 extremes of severity: patients with the Indian/Arabian haplotype have the mildest course of disease, while those with the Bantu haplotype exhibit the most severe course. Nucleotide -530 is a binding site for a protein called BP1 (601911), which may be a repressor of the HBB gene. BP1 binds with the highest affinity to the Indian haplotype sequence and with the weakest affinity to the Bantu sequence, which might explain the differences in clinical course in these different population groups. Zeng et al. (1994) demonstrated the same sequence at -530 bp in patients with the Arabian haplotype as in Indian sickle cell anemia patients. This supports the idea of a common origin of the sickle cell mutation in individuals in India and Saudi Arabia. Sammarco et al. (1988) presented further strong evidence that the Hb S gene in Sicily was brought by North African populations, probably during the Muslim invasions. Currat et al. (2002) studied the genetic diversity of the beta-globin gene cluster in an ethnically well-defined population, the Mandenka from eastern Senegal. The absence of recent admixture and amalgamation in this population permitted application of population genetics methods to investigate the origin of the sickle cell mutation (Flint et al., 1993) and to estimate its age. The frequency of the sickle cell mutation in the Mandenka was estimated as 11.7%. The mutation was found strictly associated with the single Senegal haplotype. Approximately 600 bp of the upstream region of the beta-globin gene were sequenced for 94 chromosomes, showing the presence of 4 transversions, 5 transitions, and a composite microsatellite polymorphism. The sequence of 22 chromosomes carrying the sickle mutation was also identical to the previously defined Senegal haplotype, suggesting that the mutation is very recent. Maximum likelihood estimates of the age of the mutation using Monte Carlo simulations were 45 to 70 generations (1,350-2,100 years) for different demographic scenarios. Embury et al. (1987) described a new method for rapid prenatal diagnosis of sickle cell anemia by DNA analysis. The first step involved a 200,000-fold enzymatic amplification of the specific beta-globin DNA sequences suspected of carrying the sickle mutation. Next, a short radiolabelled synthetic DNA sequence homologous to normal beta-A-globin gene sequences is hybridized to the amplified target sequence. The hybrid duplexes are then digested sequentially with 2 restriction endonucleases. The presence of the beta-A or beta-S gene sequence in the amplified target DNA from the patient determines whether the beta-A hybridization probe anneals perfectly or with a single nucleotide mismatch. This difference affects the restriction enzyme digestion of the DNA and the size of the resulting radiolabelled digestion products which can be distinguished by electrophoresis followed by autoradiography. The method was sufficiently sensitive and rapid that same-day prenatal diagnosis using fetal DNA was possible. The same test could be applied to the diagnosis of hemoglobin C disease. Hemoglobin C (Georgetown) also sickles. See Herrick (1910), Sherman (1940), Neel (1949), Pauling et al. (1949), Allison (1954), Ingram (1956, 1957, 1959), Chang and Kan (1981), and Shalev et al. (1988). Barany (1991) described a new assay designed to detect single base substitutions using a thermostable enzyme similar to the DNA polymerase used in PCR. This enzyme, DNA ligase, specifically links adjacent oligonucleotides only when the nucleotides are perfectly base-paired at the junction. In the presence of a second set of adjacent oligonucleotides, complementary to the first set and the target, the oligonucleotide products may be exponentially amplified by thermal cycling of the ligation reaction. Because a single base mismatch precludes ligation and amplification, it will be easily distinguished. Barany (1991) demonstrated the utility of the method in discriminating between normal and sickle globin genotypes from 10 microliter blood samples. Prezant and Fischel-Ghodsian (1992) described a trapped-oligonucleotide nucleotide incorporation (TONI) assay for the screening of a mitochondrial polymorphism and also showed that it could distinguish the genotypes of hemoglobins A/C, A/A, A/S, and S/S. The method was considered particularly useful for diagnosing mutations that do not produce alterations detectable by restriction enzyme analysis. It also requires only a single oligonucleotide and no electrophoretic separation of the allele-specific products. It represents an improved and simplified modification of the allele-specific primer extension methods. (TONI, the acronym for the method, is also the given name of the first author.) Grosveld et al. (1987) identified dominant control region (DCR) sequences that flank the human beta-globin locus and direct high-level, copy-number-dependent expression of the human beta-globin gene in erythroid cells in transgenic mice. By inserting a construct that included 2 human alpha genes and the defective human beta-sickle gene, all driven by the DCR sequences, Greaves et al. (1990) produced 2 mice with relatively high levels of human Hb S in their red cells. Use of this as an animal model for the study of this disease was suggested. Turhan et al. (2002) presented evidence suggesting that a pathogenetic mechanism in sickle cell vasoocclusion may reside in adherent leukocytes. Using intravital microscopy in mice expressing human sickle hemoglobin, they demonstrated that SS red blood cells bind to adherent leukocytes in inflamed venules, producing vasoocclusion of cremasteric venules. SS mice deficient in P- and E-selectins, which display defective leukocyte recruitment to the vessel wall, were protected from vasoocclusion. Thus, drugs targeting SS RBC-leukocyte or leukocyte-endothelial interactions might prevent or treat the vascular complications of this disease. Nitric oxide (NO), essential for maintaining vascular tone, is produced from arginine by NO synthase. Plasma arginine levels are low in sickle cell anemia, and Romero et al. (2002) reported that the sickle transgenic mouse model has low plasma arginine. They supplemented these mice with a 4-fold increase in arginine over a period of several months. Mean corpuscular hemoglobin concentration decreased and the percent high-density red cells was reduced. Romero et al. (2002) concluded that the major mechanism by which arginine supplementation reduces red cell density in these mice is by inhibiting the Ca(++)-activated K(+) channel. In a Jamaican study, Serjeant et al. (1968) described 60 patients with homozygous sickle cell disease who were 30 years of age or older, and Platt et al. (1994) estimated a median survival of 42 to 48 years. Serjeant et al. (2007) stated that the sickle cell clinic at the University of West Indies had treated 102 patients (64.7% women) who survived beyond their 60th birthday. None of the patients received hydroxyurea, and only 2 patients with renal impairment received regular transfusions. The ages of the patients ranged from 60.2 to 85.6 years. Measurement of fetal hemoglobin levels suggested that higher fetal hemoglobin levels probably conferred protection in childhood. The major clinical problems emerging with age were renal impairment and decreased levels of hemoglobin. Kwiatkowski (2005) noted that HbS homozygotes have sickle-cell disease, whereas heterozygosity confers a 10-fold increase in protection from life-threatening malaria (611162) and lesser protection against mild malaria. Cholera et al. (2008) found that P. falciparum (Pf)-infected HbA/HbS erythrocytes did not bind to microvascular endothelial cells as well as Pf-infected HbA/HbA erythrocytes. Reduced binding correlated with altered display of the major Pf cytoadherence ligand on erythrocyte membranes. Cholera et al. (2008) noted that this protective mechanism had features in common with that of HbC (141900.0038), and they suggested that weakening of cytoadherence interactions may influence the degree of malaria protection in HbA/HbS children. Modiano et al. (2008) adopted 2 partially independent haplotypic approaches to study the Mossi population in Burkina Faso, where both the HbS and HbC alleles are common. They showed that both alleles are monophyletic, but that the HbC allele has acquired higher recombinatorial and DNA slippage haplotypic variability or linkage disequilibrium decay and is likely older than HbS. Modiano et al. (2008) inferred that the HbC allele has accumulated mainly through recessive rather than a semidominant mechanism of selection. Gouagna et al. (2010) used cross-sectional surveys of 3,739 human subjects and transmission experiments involving 60 children and over 6,000 mosquitoes in Burkina Faso, West Africa, to test whether the HBB variants HbC and HbS, which are protective against malaria, are associated with transmission of the parasite from the human host to the Anopheles mosquito vector. They found that HbC and HbS were associated with significant 2-fold in vivo (P = 1.0 x 10(-6)) and 4-fold ex vivo (P = 7.0 x 10(-5)) increases of parasite transmission from host to vector. In addition, mean oocyte densities were particularly high in mosquitoes fed from HbS carriers. Ferreira et al. (2011) demonstrated that wildtype mice or mice expressing normal human Hb, but not mice expressing Hbs, developed experimental cerebral malaria (ECM) 6 to 12 days after infection with the murine malaria parasite, Plasmodium berghei. The Hbs mice eventually succumbed to the unrelated condition of hyperparasitemia-induced anemia. Tolerance to Plasmodium infection was associated with high levels of Hmox1 (141250) expression in hematopoietic cells, and mice expressing Hbs became susceptible to ECM when Hmox1 expression was inhibited. Hbs induced expression of Hmox1 in an Nrf2 (NFE2L2; 600492)-dependent manner, which inhibited the production of chemokines and Cd8-positive T cells associated with ECM pathogenesis. Ferreira et al. (2011) concluded that sickle hemoglobin suppresses the onset of ECM via induction of HMOX1 and the production of carbon monoxide, which inhibits the accumulation of free heme, affording tolerance to Plasmodium infection. Cyrklaff et al. (2011) found that HbS and HbC affect the trafficking system that directs parasite-encoded proteins to the surface of infected erythrocytes. Cryoelectron tomography revealed that P. falciparum generates a host-derived actin cytoskeleton within the cytoplasm of wildtype red blood cells that connects the Maurer clefts with the host cell membrane and to which transport vesicles are attached. The actin cytoskeleton and the Maurer clefts were aberrant in erythrocytes containing HbS or HbC. Hemoglobin oxidation products, enriched in HbS and HbC erythrocytes, inhibited actin polymerization in vitro and may account for the protective role in malaria. (less)
|
|
not provided
(-)
|
no classification provided
Method: phenotyping only
|
HBB-related disorder
Affected status: unknown
Allele origin:
unknown
|
GenomeConnect, ClinGen
Accession: SCV002075077.1
First in ClinVar: Feb 13, 2022 Last updated: Feb 13, 2022 |
Comment:
Variant identified in multiple registry participants. Variant interpreted as consistent with alpha thalassemia trait and reported on 02-28-2020 by Lab or GTR ID 500068. Variant … (more)
Variant identified in multiple registry participants. Variant interpreted as consistent with alpha thalassemia trait and reported on 02-28-2020 by Lab or GTR ID 500068. Variant interpreted as Pathogenic and reported on 07-21-2020 by Lab or GTR ID 1197. Variant interpreted as Pathogenic and reported on 05-26-2021 by Lab or GTR ID 20290. GenomeConnect assertions are reported exactly as they appear on the patient-provided report from the testing laboratory. GenomeConnect staff make no attempt to reinterpret the clinical significance of the variant. (less)
Observation 1:
Number of individuals with the variant: 1
Clinical Features:
Cardiac arrhythmia (present) , Abnormal intestine morphology (present) , Abnormal erythrocyte morphology (present) , Tooth malposition (present)
Indication for testing: Diagnostic
Age: 20-29 years
Sex: male
Testing laboratory: Mayo Clinic Laboratories,Mayo Clinic
Date variant was reported to submitter: 2020-02-28
Testing laboratory interpretation: Pathogenic
Observation 2:
Number of individuals with the variant: 1
Clinical Features:
Abnormality of eye movement (present) , Myopia (present) , Anxiety (present) , Depression (present) , Hyperhidrosis (present) , Cardiac arrhythmia (present) , Abnormal EKG (present) … (more)
Abnormality of eye movement (present) , Myopia (present) , Anxiety (present) , Depression (present) , Hyperhidrosis (present) , Cardiac arrhythmia (present) , Abnormal EKG (present) , Cardiomyopathy (present) , Abnormality of the cardiovascular system (present) , Hypertensive disorder (present) , Hypercholesterolemia (present) , Asthma (present) , Abnormal pattern of respiration (present) , Abnormal stomach morphology (present) , Abnormal erythrocyte morphology (present) (less)
Indication for testing: Carrier Screening
Age: 40-49 years
Sex: male
Testing laboratory: Myriad Genetic Laboratories, Inc.,Myriad Genetic Laboratories, Inc.
Date variant was reported to submitter: 2020-07-21
Testing laboratory interpretation: Pathogenic
Observation 3:
Number of individuals with the variant: 1
Clinical Features:
Abnormal delivery (present) , Pregnancy history (present) , Obesity (present) , Myopia (present) , Abnormal retinal morphology (present) , Hyperpigmentation of the skin (present) , … (more)
Abnormal delivery (present) , Pregnancy history (present) , Obesity (present) , Myopia (present) , Abnormal retinal morphology (present) , Hyperpigmentation of the skin (present) , Cutis laxa (present) , Abnormality of the musculature of the limbs (present) , Asthma (present) , Feeding difficulties (present) , Abnormal esophagus morphology (present) , Abnormal stomach morphology (present) , Abnormality of the liver (present) , Abnormal renal physiology (present) , Abnormality of urine homeostasis (present) , Abnormal inflammatory response (present) , Recurrent infections (present) , Abnormality of coagulation (present) , Bruising susceptibility (present) , Persistent bleeding after trauma (present) , Abnormality of thrombocytes (present) , Abnormal erythrocyte morphology (present) , Abnormal leukocyte morphology (present) (less)
Age: 30-39 years
Sex: female
Testing laboratory: Clinical Cytogenetics Laboratory,LabCorp
Date variant was reported to submitter: 2021-05-26
Testing laboratory interpretation: Pathogenic
|
|
click to load more click to collapse |
Germline Functional Evidence
There is no functional evidence in ClinVar for this variation. If you have generated functional data for this variation, please consider submitting that data to ClinVar. |
Citations for germline classification of this variant
HelpTitle | Author | Journal | Year | Link |
---|---|---|---|---|
Sickle Cell Disease. | Adam MP | - | 2023 | PMID: 20301551 |
HbSC disease: A time for progress. | Minniti C | American journal of hematology | 2022 | PMID: 36073655 |
Unusually High Prevalence of Stroke and Cerebral Vasculopathy in Hemoglobin SC Disease: A Retrospective Single Institution Study. | Sathi BK | Acta haematologica | 2022 | PMID: 34749363 |
Compound heterozygosity for hemoglobin S and hemoglobin E in a family of Proto-Australoid origin: a case report. | Basumatary N | Journal of medical case reports | 2021 | PMID: 34334128 |
Allosteric control of hemoglobin S fiber formation by oxygen and its relation to the pathophysiology of sickle cell disease. | Henry ER | Proceedings of the National Academy of Sciences of the United States of America | 2020 | PMID: 32527859 |
Curating the gnomAD database: Report of novel variants in the globin-coding genes and bioinformatics analysis. | Scheps KG | Human mutation | 2020 | PMID: 31553106 |
Large-scale whole-exome sequencing association studies identify rare functional variants influencing serum urate levels. | Tin A | Nature communications | 2018 | PMID: 30315176 |
Human candidate gene polymorphisms and risk of severe malaria in children in Kilifi, Kenya: a case-control association study. | Ndila CM | The Lancet. Haematology | 2018 | PMID: 30033078 |
Prevalence of β-Thalassemia Mutations among Northeastern Iranian Population and their Impacts on Hematological Indices and Application of Prenatal Diagnosis, a Seven-Years Study. | Jaripour ME | Mediterranean journal of hematology and infectious diseases | 2018 | PMID: 30002798 |
Sickle cell disease. | Kato GJ | Nature reviews. Disease primers | 2018 | PMID: 29542687 |
Hemoglobin inhibits albumin uptake by proximal tubule cells: implications for sickle cell disease. | Eshbach ML | American journal of physiology. Cell physiology | 2017 | PMID: 28356267 |
Revisiting the morbid genome of Mendelian disorders. | Abouelhoda M | Genome biology | 2016 | PMID: 27884173 |
Hb Tianshui (HBB: C.119A > G) in Compound Heterozygosity with Hb S (HBB: C.20A > T) from Odisha, India. | Meher S | Hemoglobin | 2016 | PMID: 27254408 |
Mild Microcytic Anemia in an Infant with a Compound Heterozygosity for Hb C (HBB: c.19G > A) and Hb Osu Christiansborg (HBB: c.157G > A). | Boucher MO | Hemoglobin | 2016 | PMID: 27117572 |
Hereditary Persistence of Fetal Hemoglobin Caused by Single Nucleotide Promoter Mutations in Sickle Cell Trait and Hb SC Disease. | Akinbami AO | Hemoglobin | 2016 | PMID: 26372199 |
The Prevalence of Sickle Cell Disease and Its Implication for Newborn Screening in Germany (Hamburg Metropolitan Area). | Grosse R | Pediatric blood & cancer | 2016 | PMID: 26275168 |
The compound state: Hb S/beta-thalassemia. | Figueiredo MS | Revista brasileira de hematologia e hemoterapia | 2015 | PMID: 26041415 |
Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. | Yawn BP | JAMA | 2014 | PMID: 25203083 |
Pathogenic variants for Mendelian and complex traits in exomes of 6,517 European and African Americans: implications for the return of incidental results. | Tabor HK | American journal of human genetics | 2014 | PMID: 25087612 |
Prevalence of the β(S) gene among scheduled castes, scheduled tribes and other backward class groups in Central India. | Shrikhande AV | Hemoglobin | 2014 | PMID: 25023085 |
Prevalence of sickle cell disease in a pediatric population suffering from severe infections: a Congolese experience. | Kondani DA | Hemoglobin | 2014 | PMID: 25023084 |
Influence of the βs haplotype and α-thalassemia on stroke development in a Brazilian population with sickle cell anaemia. | Domingos IF | Annals of hematology | 2014 | PMID: 24493127 |
Exome sequencing identifies potential risk variants for Mendelian disorders at high prevalence in Qatar. | Rodriguez-Flores JL | Human mutation | 2014 | PMID: 24123366 |
The distribution of haemoglobin C and its prevalence in newborns in Africa. | Piel FB | Scientific reports | 2013 | PMID: 23591685 |
HBB loss of heterozygosity in the hemopoietic lineage gives rise to an unusual sickle-cell trait phenotype. | Joly P | Haematologica | 2013 | PMID: 23065522 |
An empirical estimate of carrier frequencies for 400+ causal Mendelian variants: results from an ethnically diverse clinical sample of 23,453 individuals. | Lazarin GA | Genetics in medicine : official journal of the American College of Medical Genetics | 2013 | PMID: 22975760 |
Candidate human genetic polymorphisms and severe malaria in a Tanzanian population. | Manjurano A | PloS one | 2012 | PMID: 23144702 |
Candidate polymorphisms and severe malaria in a Malian population. | Toure O | PloS one | 2012 | PMID: 22957039 |
Hb S [β6(A3)Glu→Val, GAG>GTG] and β-globin gene cluster haplotype distribution in Mauritania. | Veten FM | Hemoglobin | 2012 | PMID: 22625666 |
Hb S-São Paulo: a new sickling hemoglobin with stable polymers and decreased oxygen affinity. | Jorge SE | Archives of biochemistry and biophysics | 2012 | PMID: 22244832 |
Hemoglobins S and C interfere with actin remodeling in Plasmodium falciparum-infected erythrocytes. | Cyrklaff M | Science (New York, N.Y.) | 2011 | PMID: 22075726 |
In silico analysis of single nucleotide polymorphism (SNPs) in human β-globin gene. | Alanazi M | PloS one | 2011 | PMID: 22028795 |
A novel sickling hemoglobinopathy. | McFarlane A | The New England journal of medicine | 2011 | PMID: 22010933 |
Sickle hemoglobin confers tolerance to Plasmodium infection. | Ferreira A | Cell | 2011 | PMID: 21529713 |
Bone marrow necrosis and sickle cell crisis associated with double heterozygosity for HbS and HbOARAB. | Rossi P | American journal of hematology | 2011 | PMID: 20954261 |
A family study of HbS in a Malay family by molecular analysis. | Hafiza A | The Malaysian journal of pathology | 2010 | PMID: 21329186 |
Hemoglobin S/hemoglobin City of Hope compound heterozygote with a SubSaharan genetic background and severe bone marrow hypoplasia. | Paradisi I | Investigacion clinica | 2010 | PMID: 21302591 |
Sickle-cell disease. | Rees DC | Lancet (London, England) | 2010 | PMID: 21131035 |
Global distribution of the sickle cell gene and geographical confirmation of the malaria hypothesis. | Piel FB | Nature communications | 2010 | PMID: 21045822 |
A map of human genome variation from population-scale sequencing. | 1000 Genomes Project Consortium | Nature | 2010 | PMID: 20981092 |
A new sickling variant 'Hb S-Wake β[(Glu6Val-Asn139 Ser)]' found in a compound heterozygote with Hb S β(Glu6Val) coinherited with homozygous α-thalassemia-2: phenotype and molecular characteristics. | Kutlar F | Acta haematologica | 2010 | PMID: 20861612 |
Hearing impairment in persons with the hemoglobin SC genotype. | Onakoya PA | Ear, nose, & throat journal | 2010 | PMID: 20628988 |
Genetic variation in human HBB is associated with Plasmodium falciparum transmission. | Gouagna LC | Nature genetics | 2010 | PMID: 20305663 |
Compound heterozygosity for hemoglobin S [beta6(A3)Glu6Val] and hemoglobin Korle-Bu [beta73(E17)Asp73Asn]. | Akl PS | Laboratory hematology : official publication of the International Society for Laboratory Hematology | 2009 | PMID: 19758965 |
Genome-wide and fine-resolution association analysis of malaria in West Africa. | Jallow M | Nature genetics | 2009 | PMID: 19465909 |
Simple, efficient, and cost-effective multiplex genotyping with matrix assisted laser desorption/ionization time-of-flight mass spectrometry of hemoglobin beta gene mutations. | Thongnoppakhun W | The Journal of molecular diagnostics : JMD | 2009 | PMID: 19460936 |
Newborn screening for hemoglobinopathies in California. | Michlitsch J | Pediatric blood & cancer | 2009 | PMID: 19061217 |
Impaired cytoadherence of Plasmodium falciparum-infected erythrocytes containing sickle hemoglobin. | Cholera R | Proceedings of the National Academy of Sciences of the United States of America | 2008 | PMID: 18192399 |
Haemoglobin S and haemoglobin C: 'quick but costly' versus 'slow but gratis' genetic adaptations to Plasmodium falciparum malaria. | Modiano D | Human molecular genetics | 2008 | PMID: 18048408 |
Elderly survivors with homozygous sickle cell disease. | Serjeant GR | The New England journal of medicine | 2007 | PMID: 17287491 |
How malaria has affected the human genome and what human genetics can teach us about malaria. | Kwiatkowski DP | American journal of human genetics | 2005 | PMID: 16001361 |
Hb Hope [beta136(H14)Gly-->Asp (GGT-->GAT)]: interactions with Hb S [beta6(A3)Glu-->Val (GAG-->GTG)], other variant hemoglobins and thalassemia. | Ingle J | Hemoglobin | 2004 | PMID: 15658184 |
A novel sickle hemoglobin: hemoglobin S-south end. | Luo HY | Journal of pediatric hematology/oncology | 2004 | PMID: 15543018 |
A human embryonic hemoglobin inhibits Hb S polymerization in vitro and restores a normal phenotype to mouse models of sickle cell disease. | He Z | Proceedings of the National Academy of Sciences of the United States of America | 2002 | PMID: 12124399 |
Primary role for adherent leukocytes in sickle cell vascular occlusion: a new paradigm. | Turhan A | Proceedings of the National Academy of Sciences of the United States of America | 2002 | PMID: 11880644 |
Arginine supplementation of sickle transgenic mice reduces red cell density and Gardos channel activity. | Romero JR | Blood | 2002 | PMID: 11830454 |
Molecular analysis of the beta-globin gene cluster in the Niokholo Mandenka population reveals a recent origin of the beta(S) Senegal mutation. | Currat M | American journal of human genetics | 2002 | PMID: 11741197 |
Peculiar elongated and sickle-shaped red blood corpuscles in a case of severe anemia. 1910. | Herrick JB | The Yale journal of biology and medicine | 2001 | PMID: 11501714 |
Hb Köln [beta98(FG5)Val-->Met]: the first case found in a Chinese family. | Chang JG | Hemoglobin | 1998 | PMID: 9859938 |
Sequence of the -530 region of the beta-globin gene of sickle cell anemia patients with the Arabian haplotype. | Zeng FY | Human mutation | 1994 | PMID: 8199597 |
Mortality in sickle cell disease. Life expectancy and risk factors for early death. | Platt OS | The New England journal of medicine | 1994 | PMID: 7993409 |
Why are some genetic diseases common? Distinguishing selection from other processes by molecular analysis of globin gene variants. | Flint J | Human genetics | 1993 | PMID: 8462981 |
A novel sickle cell mutation of yet another origin in Africa: the Cameroon type. | Lapouméroulie C | Human genetics | 1992 | PMID: 1376298 |
Trapped-oligonucleotide nucleotide incorporation (TONI) assay, a simple method for screening point mutations. | Prezant TR | Human mutation | 1992 | PMID: 1301203 |
Genetic disease detection and DNA amplification using cloned thermostable ligase. | Barany F | Proceedings of the National Academy of Sciences of the United States of America | 1991 | PMID: 1986365 |
Polymerization and solubility of recombinant hemoglobins alpha 2 beta 2 (6Val) (Hb S) and alpha 2 beta 2(6Leu) (Hb Leu). | Adachi K | Hemoglobin | 1991 | PMID: 1802884 |
A transgenic mouse model of sickle cell disorder. | Greaves DR | Nature | 1990 | PMID: 2296310 |
Sickle cell trait in a white Jewish family presenting as splenic infarction at high altitude. | Shalev O | American journal of hematology | 1988 | PMID: 3354556 |
Direct sequencing of enzymatically amplified human genomic DNA. | Engelke DR | Proceedings of the National Academy of Sciences of the United States of America | 1988 | PMID: 3267215 |
Molecular basis and prenatal diagnosis of beta-thalassemia. | Kazazian HH Jr | Blood | 1988 | PMID: 3048433 |
Evidence of the African origin of sickle cell hemoglobin in western Sicily. | Sammarco P | Hemoglobin | 1988 | PMID: 2898460 |
Structural analysis of the 5' flanking region of the beta-globin gene in African sickle cell anemia patients: further evidence for three origins of the sickle cell mutation in Africa. | Chebloune Y | Proceedings of the National Academy of Sciences of the United States of America | 1988 | PMID: 2898142 |
Beta S gene in Sicily is in linkage disequilibrium with the Benin haplotype: implications for gene flow. | Ragusa A | American journal of hematology | 1988 | PMID: 2893541 |
Rapid prenatal diagnosis of sickle cell anemia by a new method of DNA analysis. | Embury SH | The New England journal of medicine | 1987 | PMID: 3821796 |
Position-independent, high-level expression of the human beta-globin gene in transgenic mice. | Grosveld F | Cell | 1987 | PMID: 3690667 |
Globin gene-associated restriction-fragment-length polymorphisms in southern African peoples. | Ramsay M | American journal of human genetics | 1987 | PMID: 2891298 |
Effect of amino acid at the beta 6 position on surface hydrophobicity, stability, solubility, and the kinetics of polymerization of hemoglobin. Comparisons among Hb A (Glu beta 6), Hb C (Lys beta 6), Hb Machida (Gln beta 6), and Hb S (Val beta 6). | Adachi K | The Journal of biological chemistry | 1987 | PMID: 2888754 |
Geographical survey of beta S-globin gene haplotypes: evidence for an independent Asian origin of the sickle-cell mutation. | Kulozik AE | American journal of human genetics | 1986 | PMID: 3752087 |
Clinical presentation of homozygous sickle cell disease. | Bainbridge R | The Journal of pediatrics | 1985 | PMID: 2582106 |
Hematologically and genetically distinct forms of sickle cell anemia in Africa. The Senegal type and the Benin type. | Nagel RL | The New England journal of medicine | 1985 | PMID: 2579336 |
Evidence for the multicentric origin of the sickle cell hemoglobin gene in Africa. | Pagnier J | Proceedings of the National Academy of Sciences of the United States of America | 1984 | PMID: 6584911 |
Origin of the beta S-globin gene in blacks: the contribution of recurrent mutation or gene conversion or both. | Antonarakis SE | Proceedings of the National Academy of Sciences of the United States of America | 1984 | PMID: 6583683 |
Use of restriction endonucleases for mapping the allele for beta s-globin. | Wilson JT | Proceedings of the National Academy of Sciences of the United States of America | 1982 | PMID: 6285354 |
Linkage of beta-thalassaemia mutations and beta-globin gene polymorphisms with DNA polymorphisms in human beta-globin gene cluster. | Orkin SH | Nature | 1982 | PMID: 6280057 |
Direct identification of sickle cell anemia by blot hybridization. | Geever RF | Proceedings of the National Academy of Sciences of the United States of America | 1981 | PMID: 6272289 |
Sickle gene. Its origin and diffusion from West Africa. | Mears JG | The Journal of clinical investigation | 1981 | PMID: 6268660 |
Evolution of the hemoglobin S and C genes in world populations. | Kan YW | Science (New York, N.Y.) | 1980 | PMID: 7384810 |
Antenatal diagnosis of sickle-cell anaemia by D.N.A. analysis of amniotic-fluid cells. | Kan YW | Lancet (London, England) | 1978 | PMID: 81926 |
Identification of a nondeletion defect in alpha-thalassemia. | Kan YW | The New England journal of medicine | 1977 | PMID: 909565 |
Relatively benign sickle-cell anaemia in 60 patients aged over 30 in the West Indies. | Serjeant GR | British medical journal | 1968 | PMID: 4232783 |
THE FIRST OBSERVATION OF HOMOZYGOUS HEMOGLOBIN S-ALPHA THALASSEMIA DISEASE AND TWO TYPES OF SICKLE CELL THALASSEMIA DISEASE: (A) SICKLE CELL-ALPHA THALASSEMIA DISEASE, (B) SICKLE CELL-BETA THALASSEMIA DISEASE. | AKSOY M | Blood | 1963 | PMID: 14084634 |
Abnormal human haemoglobins. III. The chemical difference between normal and sickle cell haemoglobins. | INGRAM VM | Biochimica et biophysica acta | 1959 | PMID: 13852872 |
Gene mutations in human haemoglobin: the chemical difference between normal and sickle cell haemoglobin. | INGRAM VM | Nature | 1957 | PMID: 13464827 |
A specific chemical difference between the globins of normal human and sickle-cell anaemia haemoglobin. | INGRAM VM | Nature | 1956 | PMID: 13369537 |
Protection afforded by sickle-cell trait against subtertian malareal infection. | ALLISON AC | British medical journal | 1954 | PMID: 13115700 |
Further studies on hemoglobin C. I. A description of three additional families segregating for hemoglobin C and sickle cell hemoglobin. | NEEL JV | Blood | 1953 | PMID: 13066514 |
Sickle cell anemia a molecular disease. | PAULING L | Science (New York, N.Y.) | 1949 | PMID: 15395398 |
Chang, J. C., Temple, G. F., Trecartin, R. F., Kan, Y. W. Beta-zero thalassemia: a nonsense mutation in man, and its correction in vitro. (Abstract) Clin. Res. 27: 457A, 1979. | - | - | - | - |
http://www.egl-eurofins.com/emvclass/emvclass.php?approved_symbol=HBB | - | - | - | - |
http://www.ncbi.nlm.nih.gov/books/NBK1377/ | - | - | - | - |
https://globin.bx.psu.edu/hbvar/menu.html | - | - | - | - |
Sherman, I. J. The sickling phenomenon, with special reference to the difference of sickle cell anemia from the sickle cell trait. Bull. Johns Hopkins Hosp. 67: 309-324, 1940. | - | - | - | - |
click to load more click to collapse |
Text-mined citations for rs334 ...
HelpRecord last updated Nov 03, 2024
This date represents the last time this VCV record was updated. The update may be due to an update to one of the included submitted records (SCVs), or due to an update that ClinVar made to the variant such as adding HGVS expressions or a rs number. So this date may be different from the date of the “most recent submission” reported at the top of this page.